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 RESUMO 
 
 O principal tratamento para os doentes com esquizofrenia é a medicação psicotrópica, 
contudo os mecanismos de acção destes medicamentos ainda não são completamente 
compreendidos. Assim, neste projecto foi realizado o subfraccionamento do proteoma de 
amostras de cortex prefrontal de ratinhos cronicamente tratados com medicação psicotrópica 
(Haloperidol, Citalopram e Clozapina). A fracção solúvel foi primeiramente analisada por 
cromatografia líquida acoplada à espectrometria de massa sequencial (LC-MS/MS) e 
aproximadamente 1500 proteínas foram identificadas no controlo e em cada condição de 
medicamento. Posteriormente, 489 proteínas foram quantificadas com elevada confiança 
usando um método quantitativo sem recurso a marcação (SWATH). A clozapina apresentou 
39, o citalopram 23 e o haloperidol 19 proteínas diferencialmente reguladas (usando um p < 
0.05 e/ou um aumento ou diminuição de 1.5× como limite) e isto pode explicar os diferentes 
efeitos observados pelos medicamentos revelando diferentes mecanismos de acção. Nas três 
condições foram encontradas 14 proteínas com p < 0.05 e 3 dessas apresentavam p < 0.01. A 
maioria das proteínas alteradas estão no metabolismo, embora outros processos relacionados 
com a esquizofrenia também foram identificados (via apoptótica, imune e homeostase do 
cálcio). A elevada expressão da proteína CaMKIIα por todos os medicamentos e da proteína 
EAAT2 em consequência da administração de clozapina, bem como, a diminuição da calretinina 
pelo uso da clozapina pode ser importante, uma vez que pode ser um mecanismo de 
compensação na doença. Todas estas descobertas podem abrir novos caminhos estratégicos 
para o tratamento e prevenção da progressão da esquizofrenia, uma vez que apontam para 
novas direcções no conhecimento das alterações relacionadas com a doença.  
 
Palavras chave: Medicação psicotrópica, esquizofrenia, cortex prefrontal, 
subfractionamento do proteoma, LC-MS/MS, análise SWATH. 

 ABSTRACT 
 
Psychotic medication is the main treatment for schizophrenia (SCZ) patients, however 
their long-term mechanisms of action are not completely understood. Thus, in this project a 
subproteome fractionation was performed using prefrontal cortex samples of mice, chronic 
treated with psychotropic drugs (Haloperidol, Citalopram and Clozapine). The soluble fraction 
were firstly analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and 
around 1500 proteins were identified in control and each drug condition. Then, 489 proteins 
were quantified with high confidence using a label free quantitative method (SWATH). The 
clozapine presented 39, the citalopram 23, and Haloperidol 19 differentially regulated proteins 
(using a p < 0.05 and/or 1.5 fold change as cut off) and this could explain the different effects 
observed by the drugs revealed different mechanisms of action. In the three drug conditions 
14 proteins presented a p < 0.05 and 3 of them a p < 0.01. The majority of the changed 
proteins were involved in the metabolism, although other processes related with SCZ were 
identified (apoptotic, immune pathways and calcium homeostasis). The increased expression 
of the proteins CaMKIIα by all the drugs and the EAAT2 in consequence of clozapine 
administration, as well as, the down regulation of the Calretinin by the use of clozapine could 
be important, once it may be a compensatory mechanism of the regulation in the disease. 
Altogether, these findings can give new insights of future strategies for the treatment and 
prevention of the progression of SCZ once it shows new directions for recognizing disease-
related changes.  
 
Keywords: Psychotropic medication; schizophrenia, prefrontal cortex; subproteome 
fractionation; LC-MS/MS, SWATH analysis.  
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1. INTRODUCTION 
1.1. Schizophrenia  
 
In 1911 Paul Eugen Bleuler introduced the term ‘‘schizophrenia’’ as a description of a 
brain disease, which replaced Kraepelin’s term dementia praecox (Bob and Mashour, 2011). 
This new name comes from the Greek schizen, that means to split, and phren that means soul 
(Fusar-Poli and Politi, 2008). 
Schizophrenia (SCZ) is a severe form of mental illness, which is categorized as a 
psychotic disorder (Frangou, 2008). This disease is a complex and multifactorial clinical 
disorder (Jablensky, 2013), characterized by a wide phenotypic and etiological heterogeneity 
(Tandon, Nasrallah and Keshavan, 2009), and exhibiting a variety of course and outcome 
patterns, ranging from debilitating chronic illness to recurrent episodes with remissions of 
symptoms in between or, in a small proportion of cases, complete recovery (Jablensky, 2013). 
According to the World Health Organization SCZ is ranked as the seventh greatest 
cause of disability worldwide (Frangou, 2008) and the prevalence rate for this disease is 
approximately 1% (Karam et al., 2010).  
The incidence of schizophrenia increases rapidly after puberty, peaking in the mid-
twenties. Its onset in males is particularly early, with a peak of incidence between 15 and 24 
years, while on females it increases more gradually over the age range, about 5–7 years later 
(Tiffin and Welsh, 2013).  
Patients with a diagnosis of schizophrenia tend to die 12–15 years before the average 
population, with this mortality difference increasing in recent decades (Os, van and Kapur, 
2009). Moreover the risk of suicide is much higher when compared with the general population 
(Chien and Yip, 2013). However, the main reason for increased mortality is related to physical 
causes, resulting from decreased access to medical care and increased frequency of routine 
risk factors (poor diet, little exercise, obesity, and smoking) (Os, van and Kapur, 2009). 
Although the precise societal burden of schizophrenia is difficult to estimate, because of 
the wide diversity of accumulated data and methods employed (Os, van and Kapur, 2009), the 
overall U.S. 2002 cost of schizophrenia was estimated to be $62.7 billion, with $22.7 billion 
excess direct health care cost ($7.0 billion on outpatient, $5.0 billion on drugs, $2.8 billion on 
inpatient, and $8.0 billion on long-term care) (Wu et al., 2005). 
Schizophrenia is characterized by an admixture of positive, negative, disorganization, 
mood, psychomotor, and cognitive symptoms (Carpenter and Tandon, 2013). Positive 
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symptoms involve impaired reality testing and include delusions, hallucinations, and other 
reality distortions (Tandon et al., 2009).  
Negative symptoms involve a blunting or loss of a range of affective and conative 
functions. These include impairments in affective experience and expression, abulia (loss of 
motivation), alogia (poverty of speech), anhedonia (inability to experience pleasure), avolition 
(lack of initiative), apathy (lack of interest), and reduced social drive (Elis, Caponigro and Kring, 
2013).   
Disorganization includes disorganized thoughts and speech (neologisms, poverty of 
thought content or incoherent verbal communication) and disorganized behavior 
(inappropriate or unusual actions) (Elis et al., 2013).  
In what concerns mood symptoms schizophrenia patients could exhibit increased 
emotional arousal and reactivity in conjunction with positive symptoms, as well as, significant 
depressive symptoms during the course of the disease (Tandon et al., 2009).   
Slowness of psychomotor activity is common in schizophrenia, it is variably associated 
with negative and depressive symptom clusters, and means a poor outcome. Excessive motor 
activity, often apparently purposeless, is more often associated with exacerbations of positive 
symptoms (Tandon et al., 2009). Individuals with schizophrenia show significant deficits in a 
number of different cognitive domains, including executive function, working memory and 
episodic memory (Barch and Ceaser, 2012). 
The course of schizophrenia can be divided into premorbid, prodromal, first-episode, 
and chronic phases (Abbott and Keith, 2010). In premorbid phase patients often have a subtle 
and nonspecific cognitive, motor and/or social dysfunction (Frangou, 2008), in prodromal 
phase they have a gradual onset of symptoms (misperceptions, over-valued beliefs, ideas of 
reference) prior to the onset of psychotic symptoms (Abbott and Keith, 2010). The first 
psychotic episode indicating formal onset of schizophrenia, and finally, there is a stable phase 
or plateau, when psychotic symptoms are less prominent and negative symptoms and the 
stable cognitive deficits increasing (Tandon et al., 2009).  
 
1.1.1. Etiology and Pathophysiology of Schizophrenia   
 
While an etio-pathophysiological nosology of schizophrenia and related psychotic 
disorders is currently elusive (Carpenter and Tandon, 2013) and there is, as yet, no validated 
biological marker that could assist diagnosis (Jablensky, 2013), diagnosis criteria remains 
essentially based on the Diagnostic and Statistical Manual of Mental Disorders, 5th edition from 
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2013 (Tandon et al., 2013) and on the International Classification of Diseases, 10th revised 
edition from 2003 (Tandon and Maj, 2008), which is expected to be updated in 2015 (Gaebel, 
Zielasek and Cleveland, 2013).  
Once the diagnosis is subjective, neuroimaging and cognitive testing may help to rule out 
alternatives, such as schizophrenia-like psychotic features secondary to brain or other medical 
disease (Jablensky, 2013).  
Many studies have demonstrated that the hippocampus (Föcking et al., 2011; Harrison, 
2004) and cortex (Williamson and Allman, 2012) have a central role in the neuropathology 
and pathophysiology of schizophrenia. Different approaches have been used to provide 
evidences of that importance, both in vivo (neuropsychology, structural and functional imaging) 
(Kasai et al., 2002) and post mortem (histology, morphometry, gene expression, and neuro-
chemistry) (Harrison, 2004). 
Several imaging technologies, such as functional magnetic resonance imaging, diffusion 
tensor imaging (Ross et al., 2006), structural magnetic resonance imaging, magnetic resonance 
spectroscopy, event-related potentials, magnetoencephalography (Kasai et al., 2002), positron 
emission tomography (PET), single-photon emission computed tomography (Chana et al., 
2013) and others, are techniques that allow to identify the brain abnormalities in patients with 
schizophrenia.  
Although the findings have been frequently inconsistent and the results are difficult to 
replicate, most studies have found widespread lateral and third ventricular enlargement (Kasai 
et al., 2002; Os, van and Kapur, 2009; Ross et al., 2006), and volume reduction of the 
hippocampus (Haren, van et al., 2012; Harrison, 2004; Honea et al., 2000) and cortex (Kasai et 
al., 2002; Ohtani et al., 2013; Owens et al., 2012; Williamson and Allman, 2012). The regions 
demonstrated as being affected by this disease are involved in cognitive, emotional, and 
motivational aspects of human behavior (Kasai et al., 2002). 
A major confounding factor in neuroimaging studies in general, and in studies 
investigating brain volume change over the time in particular, is the cumulative intake of 
psychotic medication. It is difficult to establish whether these changes in structural brain 
abnormalities are caused by the disease or are an effect of treatment (Haren, van et al., 2012). 
It is well known that schizophrenia aggregates in families. Although over two-thirds of 
the cases occur sporadically, having an affected family member substantially increases the risk 
of developing schizophrenia (Tandon, Keshavan and Nasrallah, 2008). Several genes and 
environmental factors have been associated with this disease (Bertolino and Blasi, 2009; Bray 
et al., 2010; Hosak, 2013; Modinos et al., 2013). About 60% of schizophrenic patients do not 
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have an affected first-degree relative, and about 40% of the monozygotic twins of schizophrenia 
patients remain healthy, leading to an estimated heritability of around 60–80 % demonstrating 
that genetic risk alone does not explain the full picture (Akdeniz, Tost and Meyer-Lindenberg, 
2014). In schizophrenia, environmental factors are proposed to play a role up to 60% (Schmitt 
et al., 2014). The risk of schizophrenia increases with some factors such as cannabis abuse, 
urbanicity, immigration, physical and psychological abuse, parental lost, obstetric complications 
and inflammation during pregnancy (Os, van and Kapur, 2009; Ratajczak, Wozniak and 
Nowakowska, 2013; Schmitt et al., 2014; Akdeniz et al., 2014;,Tandon et al., 2008).   
It is now generally accepted that schizophrenia is a polygenic disorder (Bray et al., 2010) 
although, finding these susceptibility genes has proven to be extremely difficult (Bertolino and 
Blasi, 2009; O’Tuathaigh et al., 2007).  
The nature of human psychopathology seriously confounds efforts to create valid animal 
models of schizophrenia at the level of behavior (Kirby, Waddington and O’Tuathaigh, 2010). 
The literature describe four basic groups of animal models of schizophrenia, such as: models 
created by pharmacological intervention, genetic models, lesion models, and models of 
developmental disorders of primary brain structures. None of the models is perfect as none 
of them reflects the full clinical picture observed in humans (Ratajczak et al., 2013). 
 Nevertheless gene disruption, either by deletion (knockouts) or insertion/over-
expression (transgenic/knock-in), with increasing conditional control over the spatial or 
temporal expression of the mutation are used for the breeding of mutant mice with the 
objective to clarify the functional roles of genes and their encoded proteins at a mechanistic 
level, to identify novel therapeutic targets and to feed into clinical studies so as to resolve 
phenotypic relationships and evaluate those targets (Kirby et al., 2010). Given the likely 
polygenic basis of the disorder, neither partial or complete loss of function nor overexpression 
of any single gene in mice is likely to produce an animal model with construct validity for 
schizophrenia (O’Tuathaigh et al., 2007). 
Altered neurotransmission has been appointed as one of the principal pathophysiological 
mechanism underlying the expression of schizophrenia symptoms (Frangou, 2008). Many 
studies established that the dopaminergic system is implicated in schizophrenia (Broome et al., 
2005; Chana et al., 2013; Jean Lud Cadet, Subramaniam Jayanthi, Michael T. McCoy, Genevieve 
Beauvais and Cai, 2010). Dopamine (DA), is the most abundant catecholamine 
neurotransmitter in the basal ganglia, it participates in the regulation of motor functions and 
of cognitive processes such as learning and memory (Jean Lud Cadet, Subramaniam Jayanthi, 
Michael T. McCoy, Genevieve Beauvais and Cai, 2010). Multiple indices of dopamine 
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transmission have been found altered (Abi-Dargham et al., 2009), giving rise to the “dopamine 
hypothesis in schizophrenia (Eyles, Feldon and Meyer, 2012). This hypothesis suggests that too 
much dopamine stimulation in the anterior cingulate cortex causes positive symptoms and too 
little dopamine stimulation in the dorsolateral frontal lobe causes negative symptoms/cognitive 
impairment (Eggers, 2013).  
This is supported by the observation that drugs such as amphetamine, cocaine and 
methamphetamine all increase dopaminergic transmission and are capable of inducing 
psychosis (Chana et al., 2013). Thus, given that the psychotic symptoms of schizophrenia are 
uniquely human and thus not accessible in animals, one approach adopted to induce in these 
a certain behavior like the disease is through the administration of these drugs 
(pharmacologically based models) (Kirby et al., 2010; O’Tuathaigh et al., 2007).  
Other studies use genetic models related to putative dopaminergic pathophysiology. 
Given evidences for intensified activation of sub-cortical D2 DA receptors in schizophrenia, it 
is notable that the phenotype of transgenic mice with selective over-expression of D2 
receptors in the striatum is characterized by locomotor hyperactivity in a novel environment. 
Also a hyperactive phenotype has been widely reported in mutants with knockouts or 
knockdown of the dopamine transporter (DAT) gene, this may be related to disrupted DAT–
D2 receptor interaction (Kirby et al., 2010). 
Another evidence that this system is implicated is the dysregulation in the candidate 
susceptibility gene for catechol-o-methyl transferase (COMT). This gene is linked to the 22q11 
susceptibility region, a microdeletion of chromosome 22 is associated with velocardiofacial 
syndrome or Di George syndrome, which has been linked with increased risk for 
schizophrenia (O’Tuathaigh et al., 2007;,Monks et al., 2014). COMT, encoding for the enzyme 
that degrades dopamine (Chana et al., 2013), is critically involved in DA metabolism, 
particularly in the prefrontal cortex (PFC) where functional specificity of COMT to DA 
metabolism has been proposed to derive from the low levels of DA transporters at synapses 
in PFC relative to the striatum (O’Tuathaigh et al., 2007;,Kirby et al., 2010). 
The cholinergic system has also gained importance in this disease (Chana et al., 2013; 
Scarr et al., 2013), once cholinergic neurons innervate anatomical structures implicated in 
schizophrenia and participate in processes that are altered in patients such as attention, 
working memory, and motivated behaviors (Karam et al., 2010). All functions of the cholinergic 
system are controlled by the interaction of acetylcholine with the nicotinic and muscarinic 
receptors (Scarr et al., 2013) and the most reproduced findings suggest that the problems in 
the cholinergic system in schizophrenia are not simply due to changes in levels of acetylcholine 
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(Scarr et al., 2013) but a widespread decrease in levels of muscarinic receptors (Chana et al., 
2013; Scarr et al., 2013). 
Gamma-amino-butyric-acid (GABA) has been implicated for a number of years in this 
disorder because of the reductions in GABAergic markers such as glutamic acid 
decarboxylase-67, the synthesizing enzyme for GABA, in the cortex and hippocampus (Chana 
et al., 2013; Kannan, Sawa and Pletnikov, 2013). 
Although studies on the serotonin system are far less abundant, serotonin transporter 
density has been found unaltered in schizophrenia. Whereas the stimulatory 5-HT2A receptors 
are decreased in drug naive patients, and the inhibitory 5-HT1A receptors showing increased 
densities in postmortem studies, in PET studies were found both increased and decreased 
binding (Hirvonen and Hietala, 2011). 
“NMDA hypofunction hypothesis of schizophrenia” is derived from the observations 
that drugs such as ketamine and phencyclidine that primarily block ionotropic n-methyl-d-
aspartate receptors (NMDARs) are capable of causing negative and positive symptoms (Karam 
et al., 2010). This evidences, as well as, the observation that  the kainate receptor expression 
is decreased in the cortex while hippocampal expression of subunits of the NMDA receptor 
are altered, led to the involvement of the glutamatergic system in schizophrenia (Chana et al., 
2013).  
Recent reviews have documented both the status of putative metabotropic glutamate 
receptor (mGluR) dysfunction in the pathophysiology of schizophrenia and the phenotype of 
mutation for members of this receptor family (mGluR1–8) (Kirby et al., 2010).  
Furthermore, many of the genes that have consistently been associated with 
schizophrenia, such as neuregulin-1 (NRG1), regulator of G protein signaling 4 (RGS4), 
dysbindin (DTNBP), and D-amino acid oxidase activator (DAAO) are involved in regulation 
of glutamatergic neurotransmission (Bray et al., 2010; Chana et al., 2013; Kannan et al., 2013; 
O’Tuathaigh et al., 2007).  
The neuregulins are a family of growth and differentiation factors whose effects are 
mediated via four neuregulin genes (NRG1-4)  that bind to the ErbB family of tyrosine kinase 
transmembrane receptors (ErbB1-4) (O’Tuathaigh et al., 2007). NRG1 signaling, via ErbB 
receptors and regulation of both NMDA receptors and postsynaptic density 95, has been 
implicated in neuronal differentiation and migration, synapse formation and plasticity and 
regulation of neurotransmitter expression and function (O’Tuathaigh et al., 2007; Ross et al., 
2006). A mutant mouse line that expressed only 5% of normal levels of the NMDA receptor 
subunit NR1 were developed, and exhibited hyperactivity that responded to the typical 
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antipsychotic haloperidol, but they also exhibited impaired social behaviors and reproducing 
that were partially reversed by the atypical antipsychotic clozapine (Ross et al., 2006). The 
functional role of NRG1 in schizophrenia is still uncertain, particularly since many different 
alleles and haplotypes have been implicated (O’Tuathaigh et al., 2007; Owen, Craddock and 
O’Donovan, 2005; Ross et al., 2006).  
The functional role of RGS4 in the central nervous system is largely unknown. RGS4 is 
widely expressed throughout this system and is involved in the regulation of G protein-coupled 
receptors which mediate signal transduction of DA, glutamate, GABA and several other 
neurotransmitters (O’Tuathaigh et al., 2007). There is now some evidence to suggest 
association between genetic variation at the RGS4 gene and schizophrenia, although it would 
appear that any contribution of RGS4 to schizophrenia susceptibility is modest (O’Tuathaigh 
et al., 2007). 
Dysbindin binds to both α- and β-dystrobrevin, which are components of the dystrophin 
glycoprotein complex. The dystrophin complex is found in the sarcolemma of muscle but is 
also located in postsynaptic densities in several brain areas, particularly mossy fibre synaptic 
terminals in the cerebellum and hippocampus (Owen et al., 2005). Although its functions are 
largely unknown, reduced levels of expression of dysbindin messenger RNA or protein have 
been found in schizophrenic brains raising the possibility that polymorphisms in dysbindin 
associated with schizophrenia may modulate expression level of the protein (Ross et al., 2006). 
Moreover, some data suggest that variation in DTNBP1 might confer risk by pre-synaptic 
effects on glutamate trafficking or release (Owen et al., 2005).  
The chromosome 13 locus has strong linkage regions to schizophrenia. Among other 
genes, this locus contains the G72 gene, now called the D-amino acid oxidase activator gene. 
DAOA activates D-amino acid oxidase (DAO), which oxidizes D-Serine, a coagonist at NMDA 
glutamate receptors (Ross et al., 2006). Thus, there is some biologic plausibility for DAOA and 
DAO in contributing to risk for schizophrenia, based on the glutamate hypothesis, once an 
increase in DAO enzyme activity and gene expression has been reported in post-mortem brain 
tissue from patients with schizophrenia (Kirby et al., 2010). 
There is also evidences that support the involvement of the disrupted in schizophrenia 
1 (DISC1) gene at 1q42.1, which was originally identified in a family which displayed a variety 
of psychiatric disorders with a chromosome translocation (Zhang, Feng et al., 2006). This gene 
encodes for a protein of 854 amino acids, with no obvious homology to other proteins of 
known function (Zhang, Feng et al., 2006). Examination of protein expression in post-mortem 
brain of patients with schizophrenia has also revealed altered subcellular distribution of a 
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DISC1 isoform in orbitofrontal cortex (O’Tuathaigh et al., 2007). Mutant DISC1 is proposed 
to contribute to schizophrenia susceptibility by disrupting intracellular transport, neurite 
modeling, and neuronal migration (Zhang, Feng et al., 2006).  
The evidences in all these studies are sufficient to suggest that schizophrenia is a 
progressive brain disease (Haren, van et al., 2012) and is not a neurodegenerative disease 
(Harrison, 2004; Martins-de-Souza, 2012). None of the original reports for the genes 
mentioned above is compelling alone, and there is insufficient follow-up to make informed 
judgments (Owen et al., 2005).  
There is lack of clarity concerning the relative schizophrenia risk quotient associated 
with even the most widely considered susceptibility genes regarding emergent genome-wide 
association studies (Kirby et al., 2010). 
 
1.2. Current Approaches in Schizophrenia Treatment  
 
Until the early 1950s, the treatments used in schizophrenia were: inducing a condition 
of shock with cardiazol, insulin or electrical current, or cutting the connections between the 
frontal cortex and the deeper brain regions (lobotomy) (Ellenbroek, 2011).  
The current approaches to treatments for schizophrenia still apply electroconvulsive 
shock, in a controlled manner, for specific treatment resistant cases (Ellenbroek, 2011) and 
more recently different approaches to psychosocial interventions have been used successively 
(Elis et al., 2013). However, the main-stream and standard treatment for nearly all patients is 
psychotropic medication, especially antipsychotic drugs (Miyamoto et al., 2005). And since 
subsyndromal symptoms of depression in patients with schizophrenia are common and 
clinically important, another class of psychotropic medication commonly prescribed is 
antidepressants (Dawes et al., 2012).   
An antipsychotic (or neuroleptic) is a tranquilizing psychiatric drug used primarily to 
manage psychosis. Antipsychotic drugs have been used to treat patients with schizophrenia 
and other psychotic disorders like bipolar disorders (Park, E. J. et al., 2013). These drugs can 
be divided into three groups: typical or first-generation, atypical or second-generation, and 
third-generation antipsychotics (Park, E. J. et al., 2013). 
Antipsychotics are shown to be effective against positive symptoms in patients with 
schizophrenia, however, their use alone may be limited by their inability to tackle the 
frequently occurring negative symptoms and cognitive impairments (Chien et al., 2013). 
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Moreover a continuous long-term antipsychotic therapy is required for patients with 
schizophrenia to control symptoms and reduce relapse rates (Park, E. J. et al., 2013). 
Antipsychotic drugs are monoamine receptor antagonists (Nguyen et al., 1992). All the 
currently available antipsychotics, except the third generation antipsychotics (Ellenbroek, 
2011), block the dopamine D2 receptor family (Kapur and Seeman, 2000). The third-
generation antipsychotic are a partial dopamine agonist, it means, it is an antagonist in brain 
areas with high dopamine levels and it is an agonist in areas with low dopamine activity 
(Ellenbroek, 2011). All antipsychotic medications are associated with an increased likelihood 
of sedation, sexual dysfunction, postural hypotension, cardiac arrhythmia, and sudden cardiac 
death (Muench and Hamer, 2010). 
So far, previous studies have not been able to elucidate all effects of these drugs (Chien 
et al., 2013) Therefore a promising route of investigation into the causes of the schizophrenia 
is to study how psychotic drugs alter brain function, as it can help to unravel neural 
mechanisms involved in the pathogenesis of this disorder (Critchlow et al., 2006; Konradi and 
Heckers, 2001). 
 
1.2.1. First Generation Antipsychotics 
 
Chlorpromazine was the first antipsychotic drug and its use in schizophrenic patients 
marked the beginning of a revolution in the treatment of schizophrenia in 1950’s (Chien et al., 
2013; Ellenbroek, 2011). Subsequently several other first generation antipsychotics (FGAs) 
were introduced into the market including haloperidol, and this widespread use led to a rapid 
decline in the number of patients in psychiatric institutions (Chien et al., 2013; Ellenbroek, 
2011). 
First generation antipsychotics also known as typical, conventional, classical or traditional 
antipsychotics, are classified according to their chemical structure: the Butyrophenones to which 
haloperidol belongs to; the Phenothiazines such as Chlorpromazine; and the Thioxanthenes 
(Park, E. J. et al., 2013). 
Most of all, FGAs are a relatively low-cost treatment and commonly used medication 
(Chien et al., 2013). They have satisfactory efficacy in positive symptoms reduction, however 
there is limited evidence to support their efficacy against the negative and cognitive symptoms 
(Chien et al., 2013). 
Major adverse events induced by FGAs generally include sedation, movement disorders, 
endocrine disturbance, and metabolic and electrocardiogram changes (Chien et al., 2013). 
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Nevertheless, the extrapyramidal-side-effects (EPS) may be considered the most debilitating 
side effects of these drugs, which include: pseudoparkinsonism, akathisia (characterized by a 
restless feeling), acute dystonia, and tardive dyskinesia (repetitive involuntary movements) 
(Muench and Hamer, 2010). This is primarily true for medications that bind tightly to 
dopaminergic neuro-receptors, such as haloperidol, and less likely with FGAs that have weaker 
dopamine blockade (Muench and Hamer, 2010). 
 
Haloperidol 
 
Haloperidol, which structure is represented in Figure1.1, was synthesized in 1958 by the 
Janssen Pharmaceutica (Ban, Healy and Shorter, 2004), which is now part of Johnson & Johnson 
Pharmaceutical Research and Development.  
 
 
Figure 1.1 - Chemical structure of Haloperidol (Ebrahimzadeh et al., 2013). The chemical 
designation is 4-[4-(p-chloro-phenyl)-4-hydroxypiperidino]-4’—fluorobutyrophenone and it has the following 
molecular formula: C21H23ClFNO2  and molecular weight: 375.864223g/mL. 
 
Also known by the commercial name of Haldol, is a butyrophenone derivative and was 
first marketed in the United States in 1967 (Gerace et al., 2012). 
This drug  is a first-generation antipsychotic that is widely used clinically (Park, J. et al., 
2012a). It is an effective antipsychotic agent commonly used in the treatment of schizophrenia 
and in the treatment of acute psychotic states, such as drug-induced psychosis (LSD, psilocybin, 
amphetamines, ketamine, phencyclidine) and psychosis associated with high fever or metabolic 
disease (Ebrahimzadeh et al., 2013) and delirium (Gerace et al., 2012).  
Haloperidol exert its therapeutic properties mainly by blocking D2 receptors and 
exhibits low activity at 5-HT2A, D1, and α1 and α2 adrenergic receptors, and only minimal 
affinity to 5-HT1A and histamine receptors, in contrast with second generation antipsychotics 
(Karl et al., 2006; Schmetzer, 2008). 
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In schizophrenia, haloperidol reverses positive symptoms but is not particularly effective 
against negative symptoms or cognitive deficits (Karl et al., 2006).  
Adverse reactions to haloperidol, like other FGAs, include drowsiness, blurred vision, 
extrapyramidal effects, tachycardia, hypotension and muscular rigidity (Gerace et al., 2012). 
Haloperidol is metabolized to a haloperidol pyridinium ion that is toxic and can increase 
oxidative stress and induce plasma membrane damage, which may partially explain the 
pathogenesis of haloperidol induced extrapyramidal side effects such as parkinsonism 
symptoms (Bošković et al., 2013). It has also been widely cited to induce changes in brain 
volume, including enlargement of the caudate nucleus and reductions in cortical gray matter 
(Vernon et al., 2012). 
Though a number of theories have been proposed, the precise pathophysiological 
mechanisms responsible for the development of these adverse drug reactions are not known 
(Crowley et al., 2013). Moreover, molecular and cellular adaptations responsible for its 
mechanism of action remain largely unknown. Understanding this involves the study of long-
term effects of haloperidol, not only on neurotransmitters and their receptors, but also on 
the signal transduction pathways that translate their actions on neuronal activity (Dlaboga, 
Hajjhussein and O’Donnell, 2008). 
 
1.2.2. Second Generation Antipsychotics  
 
Second Generation Antipsychotics (SGAs) are also described as atypical antipsychotics, 
due to the drug clozapine, the first SGA to be introduced (Duncan et al., 2000). Clozapine 
seemed atypical in the sense that it did not cause extra-pyramidal side effects in patients, in 
contrast to the FGAs (Kapur and Remington, 2001).  
Imaging studies suggest that while FGAs require striatal D2 occupancy of ∼75% for 
efficacy (and EPS occur at ∼80% occupancy), SGAs display <60% occupancy of striatal D2 
receptors (Wenthur and Lindsley, 2013). 
The atypical antipsychotics are classified according to their pharmacological properties 
(Park, E. J. et al., 2013), and the development of other SGAs like risperidone, olanzapine, 
quetiapine, ziprasidone, amisulpiride, sertindole, and zotepine have also gained atypical status 
(Kapur and Remington, 2001). 
The efficacy of second-generation antipsychotics on cognitive and social functioning, as 
well as other longer-term effects such as mortality and quality of life, are inconsistent (Chien 
et al., 2013). 
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SGAs have similar effects to FGAs in terms of reduction of positive and disorganization 
symptoms. Although, neither of them has convincingly proven to be effective in reducing 
negative symptoms, SGAs have more advantages against these, for the reason perhaps that 
they don´t cause extra-pyramidal side effects which can even worsen the negative symptoms 
(Lieberman and Stroup, 2005). 
The safety advantages of the atypical drugs have been questioned because of their 
propensity to induce weight gain, drowsiness, sexual dysfunction, and altered glucose and lipid 
metabolism (Ellenbroek, 2011; Lieberman and Stroup, 2005). 
The atypical agents differ pharmacologically from previous antipsychotic agents in their 
lower affinity for dopamine D2 receptors, but they have affinities for other neuro-receptors, 
including other dopaminergic (D1, D3 or D4), serotonergic (especially 5-HT2A and 5-HT2C), 
adrenergic (mainly α1) and histaminergic (especially H1) (Ellenbroek, 2011; Lieberman and 
Stroup, 2005). 
The discovery of clozapine, and similar drugs, also led to the dopamine hypothesis of 
schizophrenia, which had a high impact on the search for neurotransmitter functions. 
However, the pathophysiology of schizophrenic symptoms and the related mechanism of 
action of antipsychotics could not be fully explained (Ackenheil and Weber, 2002). 
 
Clozapine  
 
Clozapine, which structure is represented in Figure 1.2, is a generic name for the brand 
Clozaril, manufactured by Novartis (Wenthur and Lindsley, 2013). It was the first second 
generation antipsychotic to be introduced in Europe in 1971 (Park, J. et al., 2012b; Wenthur 
and Lindsley, 2013) 
 This drug was also the first antipsychotic agent that demonstrated clinical efficacy for 
positive symptoms without the risk of developing EPS (Abi-Dargham and Laruelle, 2005; 
Duncan et al., 2000), and until today clozapine remains one of the most clinically effective 
antipsychotics available (Wenthur and Lindsley, 2013).  
This unique feature of clozapine significantly broadened understanding of the mode of 
action of antipsychotics, and created new hypotheses for schizophrenia (Ackenheil and Weber, 
2002). 
The common adverse effects of the SGAs have also been associated with clozapine 
(Wenthur and Lindsley, 2013), such as metabolic syndrome, specially weight gain (Chien et al., 
2013). Nonetheless, other serious effects have been reported, in fact, clozapine was removed 
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from the market in 1975 because of its risk for agranulocytosis, an acute condition resulting 
in lowered white blood cell count (commonly neutrophils), placing patients at high risk of 
infections due to suppressed immune system (Abi-Dargham and Laruelle, 2005; Park, J. et al., 
2012b; Wenthur and Lindsley, 2013). 
 
Clozapine was then reintroduced in 1989, since patients who are resistant to treatment 
with typical antipsychotics remain a major therapeutic challenge in schizophrenia, and 
clozapine was shown to be the gold standard treatment for this patient group (Abi-Dargham 
and Laruelle, 2005; Cacabelos, Hashimoto and Takeda, 2011; Chandrappa and Ho, 2012; 
Duncan et al., 2000).  
Clozapine is a tricyclic benzodiazepine and an example of polypharmacology, once this 
drug and its active metabolite norclozapine (N-desmethylclozapine) has affinity for several 
receptors (Wenthur and Lindsley, 2013). It has low affinity, with only 40−60% occupancy, and 
a fast dissociation from dopamine D2 receptors, in contrast with >80% occupancy by FGAs, 
which may account for the lack of extrapyramidal side effects (Kapur and Seeman, 2000). The 
chemical structure of clozapine facilitates a relatively rapid dissociation from D2 receptors 
(Seeman, 2014). It shows high affinity for serotonin receptors, specially 5-HT2A receptor, but 
also muscarinic, cholinergic, histamine and preference for others dopaminergic receptors, such 
as D1 and D4 over D2 (Ellenbroek, 2011).  
The high affinity of clozapine, which occupies almost all (actually 96%) of the 5HT2A 
receptors (Seeman, 2014), was suggested to contribute to its reduced side-effect liability, 
greater efficacy and its activity in therapy-resistant schizophrenia (Schmidt et al., 1995). 
However new studies propose that the great difference between the serotonin 5HT2A and D2 
 
Figure 1.2 - Chemical structure of Clozapine (Seeman, 2014). The chemical designation is 8-Chloro-
11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine and it has the following molecular formula: 
C18H19CIN4 and molecular weight: 326.82326g/mL. 
 
14 | I N T R O D U C T I O N  
 
 
affinities in atypical antipsychotics was not due to higher 5HT2A affinities but to lower D2 
affinities (Seeman, 2014). 
Thus, the observed clinical efficacy of clozapine can be accounted for almost all of the 
prevailing hypotheses used to explain the etiology of schizophrenia (Wenthur and Lindsley, 
2013). Despite of these intense studies, the precise molecular underpinnings that account for 
clozapine’s unique efficacy remain elusive (Wenthur and Lindsley, 2013).  
 
1.2.3. Antidepressants  
 
Depressive symptoms occur in a large set of patients with schizophrenia and may be 
present throughout all phases of this disease (Lako et al., 2012).  
Negative and cognitive symptoms in schizophrenia are generally poorly responsive to 
antipsychotic drug treatment (Dawes et al., 2012; Iancu et al., 2010). Therefore various 
augmentation strategies are used, among them the combination of the antipsychotic with an 
antidepressant (Rummel, Kissling and Leucht, 2005).  
Antidepressants can be distributed according to their mechanism of action into several 
groups (Lôo et al., 2004) such as monoamine re-uptake inhibitors (which comprises tricyclic 
antidepressants, and selective serotonin re-uptake inhibitors (SSRIs)), psychostimulant 
antidepressants, receptor antagonists, and monoamine oxidase inhibitors (Howard et al., 
2012).  
All antidepressants enhance transmission of one or more monoamines, either by 
reuptake inhibition, enzyme inhibition or activity at pre- or postsynaptic receptors (Howard 
et al., 2012). Although increased monoamine transmission occurs within hours, the 
antidepressant effect is slower to appear because this requires normalization of receptor 
sensitivity and neuroplasticity (Howard et al., 2012). 
Several studies suggest that selective SSRIs, which citalopram belongs to, have the 
potential for ameliorating the negative symptomatology of schizophrenia patients (Dawes et 
al., 2012; Iancu et al., 2010). 
The tricyclic antidepressants (TCA) were the first drugs to be considered 
antidepressants. The SSRIs are newer and largely replaced the TCA because they show a 
similar efficacy with less significant side effects (Ables and Baughman, 2003; Fitzgerald and 
Bronstein, 2013; Helmut Buschmann, Jörg Holenz and Vela, 2007). Common side effects of 
SSRIs include transient nausea, diarrhea, insomnia, somnolence, dizziness, akathisia, and long-
term orgasmic dysfunction (Ables and Baughman, 2003; Gordon, 2013). 
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SSRIs block the reuptake of serotonin (5-HT1A, 5-HT2C, 5-HT2C, and 5-HT3C) into the 
presynaptic nerve terminal, thereby enhancing serotonin neurotransmission (Ables and 
Baughman, 2003; Gordon, 2013; Nutt et al., 1999). Atypical antipsychotics antagonize both 
serotonin and dopamine receptors, so this antagonism is, however, often confounded by co-
administration of antidepressants (Sheremata and Chen, 2004). 
The developments in the future are likely to remain focused on monoamine 
neurotransmitters, with the aim of finding agents that are either more effective, better 
tolerated or that have a faster onset of action than the existing options (Nash and Nutt, 2007). 
 
Citalopram  
 
 Citalopram, which structure is represented in Figure 1.3, marketed as Celexa, was 
originally created in 1989, by the pharmaceutical company Lundbeck.  
 
 It is a selective serotonin reuptake inhibitor, and was approved to treat depression 
becoming available in the United States in 1998 (Vieweg et al., 2012).  
 The use of antipsychotic treatment with this antidepressant drug results in a significant 
reduction of the severity of subsyndromal depressive symptoms in patients with schizophrenia 
(Dawes et al., 2012). 
As a SSRI, citalopram acts by inhibiting the neuronal uptake of serotonin with minimal 
effect on norepinephrine and dopamine (Cuenca, Holt and Hoefle, 2004), therefore it is the 
most selective of the SSRIs (Barak et al., 2003). 
 
Figure 1.3 - Chemical structure of Citalopram (Moltke, von et al., 1999). The chemical designation 
is 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile and it has the following 
molecular formula: C20H21FN2O and  molecular weight: 324.391943g/mL. 
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In addition to its ability to inhibit serotonin reuptake, citalopram has some affinity to α1-
adrenoceptors and a slight histamine H1-receptor blocking potency (Hiemke and Härtter, 
2000). 
Hepatic biotransformation of citalopram is mediated mainly by cytochrome P450 family 
of enzymes (Moltke, von et al., 1999; Vieweg et al., 2012), to form a principal metabolite, N-
desmethylcitalopram (Moltke, von et al., 1999; Unceta et al., 2013) which can be measured in 
plasma (Hiemke and Härtter, 2000).  
Side effects from citalopram include dizziness, sweating, nausea, vomiting, tremor, 
somnolence, and sinus tachycardia (Ables and Baughman, 2003; Cuenca et al., 2004). 
Nevertheless citalopram has a wide margin of safety (Brøsen and Naranjo, 2001), and 
although many of the SSRIs are reported as having many drug-drug interactions, this drug has 
low potential for drug interactions and may be appropriate in patients taking multiple 
medication and in elderly patients because of its tolerability (Ables and Baughman, 2003).  
 
1.3. Proteomic Studies 
 
Schizophrenia is the result of DNA alterations and environmental factors, which 
together lead to differential protein expression and ultimately to the development of the illness 
(Martins-de-Souza, Maccarrone, et al., 2010). While genomic investigations continue to 
contribute with important insights (Föcking et al., 2011), they have not answered elementary 
questions on the pathophysiology of the disease, nor have they resulted in the identification 
of biomarkers with predictive value for disease risk or therapeutic response (Martins-de-Souza 
et al., 2012). 
Thus several proteomic studies of postmortem brain tissue from subjects with 
schizophrenia and model animals of this disease have been made (English et al., 2011; Föcking 
et al., 2011; Martins-de-Souza, 2012; Martins-de-Souza, Maccarrone, et al., 2010; Martins-de-
Souza et al., 2012; Rao et al., 2012). They have demonstrated changes in cytoskeletal, synaptic, 
metabolic, and mitochondrial proteins (English et al., 2011; Föcking et al., 2011; Martins-de-
Souza, 2012; Martins-de-Souza, Harris, et al., 2010; Martins-de-Souza, Maccarrone, et al., 2010).  
However, confounding factors such as the effects of chronic medication and sample 
heterogeneity have resulted in difficulties in interpreting the results (Martins-de-Souza et al., 
2012). This has led to the need for studies that reveal proteomic alterations induced by the 
medication usually prescribed to SCZ patients (Konopaske et al., 2013; Ma et al., 2009).  
I N T R O D U C T I O N  | 17 
 
 
One of these studies allowed the identification of 30 proteins, which functions are 
related with metabolic, signaling, transport, protein metabolism, chaperone, DNA binding and 
cell cycle categories, that are differently expressed in rats after chronic treatment with 
risperidone (O’Brien et al., 2006).   
Another study concluded that olanzapine and haloperidol alters protein expression 
associated with presynaptic function and nervous system development in rats (Ma et al., 2009).  
Haloperidol induced expression of proteins linked to oxidative stress and apoptosis 
while risperidone activated growth regulating metabolic pathways were the conclusion of a 
study in neural stem cells treated with these drugs (Ahmed et al., 2012).  
Another proteomic study proved that MK-801, a glutamergic antagonist, induced 
changes in the levels of three proteins in both cortex and thalamus and clozapine reversed all 
these protein changes whereas haloperidol reversed only two. Furthermore both 
antipsychotics induced new protein changes in both cortex and thalamus not seen after MK-
801-treatment alone (Paulson et al., 2007). Also haloperidol increased both c-fos and zif268 
mRNA level in the caudate-putamen but clozapine only altered zif268 mRNA levels in the 
same region (Nguyen et al., 1992).   
Another study concluded that  chronic treatment with escitalopram (a (S)-stereoisomer 
(enantiomer) of the drug citalopram) only affects the expression of a few of the proteins that 
were altered in rats that were separated from the progenitor at birth (which serve as 
depression model) and it targets another group of cytosolic proteins to achieve its therapeutic 
effect (Marais et al., 2009).  
These studies are essential to distinguish possible confounding factors as proteomic 
alterations due to chronic drug medication from disease alterations (Martins-de-Souza, 
Maccarrone, et al., 2010). They can also help to reveal the mechanisms of action of these drugs, 
what could explain some adverse effects caused by them and giving clues about the 
pathogenesis of the disease (Critchlow et al., 2006). Finding new targets and more effective 
and safe drugs could also be possible.  
 
2. NEUROPROTEOMICS TECHNIQUES  
 
Neuroproteomics is a subset of the proteomics field concerned with increasing basic 
biological mechanisms understanding and finding biomarkers of central nervous system 
diseases or drug response to improve understanding of the pathophysiology of brain disease 
(English et al., 2011). 
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While other methods such as two-dimensional polyacrylamide gel electrophoresis (2DE) 
continue to be used, a variety of more in-depth mass spectrometry-based approaches including 
both label (ICAT, iTRAQ, TMT, SILAC, SILAM), label-free (MRM, SWATH®) and absolute 
quantification methods, are rapidly being applied to neurobiological investigations (Craft, Chen 
and Nairn, 2013). 
2DE has some disadvantages such as its lack of ability to widen the protein dynamic range 
as well as the inability to analyze hydrophobic or very high or low molecular weight proteins 
(Martins-de-Souza, Maccarrone, et al., 2010). One alternative to 2DE is the non-gel “bottom-
up” liquid chromatography-coupled mass spectrometry-based shot-gun proteomics (Wang et 
al., 2008). This methodology consists of the digestion of a given proteome, using a proteolytic 
enzyme (typically trypsin that cleaves at the C-terminal of arginine and lysine) (Kicman, Parkin 
and Iles, 2007), followed by multi-dimensional separation of the resultant peptides, generally 
using high-performance liquid chromatography (HPLC) coupled to tandem mass spectrometry 
(MS/MS) (Martins-de-Souza et al., 2012). Protein digestion has the advantage of reducing 
proteins to peptides, more amenable to be identified in bottom-up LC-MS analysis (Meent, 
van de and Jong, de, 2011). 
Although some successes using stable isotopic labeling technology for protein 
quantification have been reported, it remains technically difficult to comprehensively 
characterize the global proteome due to the high costs of the labeling reagents and the nature 
of the methodology (Wang et al., 2008). Recently, label-free approaches have emerged as high-
throughput methods for proteomics studies (Megger et al., 2013). This provides a powerful 
tool to resolve and identify thousands of proteins from a complex biological sample (Wang et 
al., 2008). Furthermore, this technique is apparently the easiest way of comparing proteomes, 
not only because labeling is not required but also because there are no limits regarding the 
number of samples that can be compared, which is an advantage for large clinical studies 
(Martins-de-Souza et al., 2012). 
Of the distinct label-free proteomics approaches that can be used, the one that has been 
used most in SCZ studies is data-independent analysis (Martins-de-Souza et al., 2012). The 
data-independent mode of acquisition has been demonstrated to be the most-accurate label-
free approach for estimating absolute/relative protein abundance (Craft et al., 2013). 
Independently of the proteomic screening method chosen, sample preparation is a 
decisive step of any proteomic analysis as this step determines the number and type of proteins 
in the final proteome. The loss of particular classes of proteins during sample preparation will 
lead to the underrepresentation of potential biomarkers that can be pivotal to the studied 
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proteome. Considering the high proteome complexity of some tissues, the use of 
methodologies leading to generation of subproteomes may be advisable in order to obtain the 
most complete proteome possible for a given sample (Martins-de-Souza et al., 2012). 
 
2.1. LIQUID CHROMATOGRAPHY COUPLED TO TANDEM MASS 
SPECTROMETRY (LC-MS/MS) 
 
Liquid chromatography (LC) coupled with mass spectrometry is the predominant 
platform used to analyze proteomic samples because of its sensitivity, selectivity, accuracy, 
speed and throughput (Chen, G. and Pramanik, 2009; Meent, van de and Jong, de, 2011; Xie, 
Smith and Shen, 2012). 
A single-dimension LC separation is one of the basic elements in LC–MS-based 
proteomics. High-performance liquid chromatography (HPLC) is the term used to describe 
LC in which the liquid mobile phase is mechanically pumped at high pressure through a column 
that contains the stationary phase (Weston and Brown, 1997). 
Reversed phase (RP) is the most common LC format for separation of peptides (Xie et 
al., 2012). The separation principle of RP is based on the polarity of the analytes under 
conditions where the stationary phase (silica derivatized C18 resins, are the most often used) 
is more hydrophobic than the mobile phase (usually a mixture of acetonitrile and water with 
an acidic ion-pairing reagent that should have an excellent compatibility with mass 
spectrometry (MS)) (Božović and Kulasingam, 2013; Palma, Di et al., 2012). As a result, a 
decrease in the polarity of the mobile phase results in a decrease in solute retention (Weston 
and Brown, 1997). 
Essentially, MS measures the mass-to-charge ratio (m/z) of gas-phase ions. Mass 
spectrometers consist of an ion source that converts analyte molecules into gas-phase ions, a 
mass analyzer that separates ionized analytes on the basis of m/z ratio, and a detector that 
records the number of ions at each m/z value (Figure 2.1) (Han, X., Aslanian and Yates, 2008). 
 The development of electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization, the two soft ionization techniques capable of ionizing peptides or 
proteins, revolutionized protein analysis using MS (Chen, G. and Pramanik, 2009; Han, X. et 
al., 2008). 
 
 
20 | I N T R O D U C T I O N  
 
 
 
 
 
 
ESI is often coupled with a chromatographic system, typically reverse phase 
chromatography, allowing the analysis of very complex samples (Wysocki et al., 2005). ESI is 
set between a HPLC and the inlet of a mass spectrometer and uses an electric field to yield a 
spray of fine droplets (Lin, Tabb and Yates, 2003). In ESI, a dilute solution is sprayed from a 
fine needle, which carries a high potential, thus the droplets will have an excess of positive 
charges. At the tip of the needle the charged droplets spray assumes a conical shape referred 
to as the Taylor cone. The smaller droplets are repelled from the needle towards the sampling 
cone on the counter electrode at the orifice of the instrument (Kicman et al., 2007). 
Evaporation of the volatile solvent results in increased Coulombic repulsion between the 
positive charges, which causes fragmentation of the droplet, generating smaller droplets 
(Figure 2.2) (Bakhtiar and Nelson, 2000). When operating at high solvent flow rates, a 
nebulization gas (or sheath gas) is needed to assist the solvent dispersion (Lin et al., 2003). 
As ions exit the ion source, they pass into a mass analyzer (Lin et al., 2003). There are 
four major types of mass analyzers commonly used: quadrupole (Q), ion trap, time-of-flight 
(TOF), and Fourier-transform ion cyclotron resonance (Han, X. et al., 2008).  
 
 
 
 
 
 
 
 
 
 
Figure 2.1 - The principle components of a mass spectrometer. Consisting of the ionization 
source followed by the mass analyzer, detector, and a data interrogation system. Adapted from (Kicman 
et al., 2007). 
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Figure 2.2 - Electrospray ionization process. A fine mist of analyte is formed from the sample stream as 
droplets are formed from the Taylor cone. The charged droplets desolvate by Coulombic explosions and ions 
free from solvent can then enter the mass spectrometer via an intermediate vacuum region (Kicman et al., 
2007) 
 
‘Hybrid’ instruments have been designed to combine the capabilities of different mass 
analyzers (Gygi and Aebersold, 2000; Han, X. et al., 2008; Lin et al., 2003). For example, 
quadrupole-TOFs are instruments that combine a quadrupole mass analyzer for ion selection 
in a tandem mass spectrometer mode and TOF analyzers to record m/z values with high 
resolution (Lin et al., 2003). The combination of a quadrupole and a TOF analyzer provides 
high sensitivity and excellent mass accuracy (Kicman et al., 2007).  
The quadrupole analyzer is a device which uses the stability of the trajectories in 
oscillating electric fields to separate ions according to their m/z ratios (Hoffmann and 
Stroobant, 2007). It consists of four mutually parallel circular metal rods such that the electric 
field between them is hyperbolic (Figure 2.3) (Kicman et al., 2007). A combination of radio 
frequency and  direct current voltages are applied to each pair of rods to produce a complex, 
oscillating movement of the ions as they move from the beginning of the mass filter to the end 
(Kinter and Sherman, 2000). 
The electrical field created in the mass analyzer could act as a filter in that it only allows 
ions of certain masses (‘resonant ions’) to pass down the gap between the four rods. Ions with 
different mass to charge ratios (non-resonant ions) will collide with the rods and become 
neutralized (Hoffmann and Stroobant, 2007; Kicman et al., 2007).  
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Figure 2.3 - Schematic diagram of a quadrupole mass filter. One pair of rods receives a superimposed 
positive direct current (DC) potential and a radio-frequency potential. The other adjacent pair of rods receives 
a negative DC potential and a radio-frequency potential of the same magnitude. Adapted from (Kicman et al., 
2007). 
 
In time-of-flight mass analyzers (Figure 2.4) an ion is given a fixed amount of kinetic 
energy by acceleration in an electric field that is generated by the application of a high voltage, 
and the ion enters a field-free region where it travels at a velocity that is inversely proportional 
to its m/z. Because of this inverse relationship, ions with lower m/z travel more rapidly than 
ions with higher m/z. The time required for the ion to travel the length of the field-free region 
is measured and used to calculate the velocity and ultimately the m/z of the ion (Kinter and 
Sherman, 2000). The most significant limit on m/z resolution in a TOF is the range of initial 
velocities of the ions as they are accelerated. A method to correct for the deleterious effects 
of initial kinetic-energy spreads is to use an ion reflector, (also referred to as a “reflectron”). 
The reflectron is an ion mirror, created by an electric field that reverses the flight path of the 
ion (Takahashi and Isobe, 2007).  
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The use of tandem mass spectrometry is the most popular approach to protein 
identification (Wysocki et al., 2005). In the case of using a hybrid instrument Q-TOF the 
tandem mass  spectrometry is designed “in space” once it has two mass analyzers (Hoffmann 
and Stroobant, 2007). In this case the quadrupole performs the mass selection of a desired 
target ion from a stream of ions produced in the ion source, then it is fragmented in a second 
quadrupole by collision induced dissociation (CID) (Chen, G. and Pramanik, 2009), and the 
TOF performs the analysis of the mass of the product ions (Kinter and Sherman, 2000). The 
term “tandem mass spectrometry” reflects the fact that two stages of mass analysis are used 
in a single experiment (Kinter and Sherman, 2000). 
CID is based on the collision between a selected molecular ion with an inert gas (rare 
gas atoms or nitrogen molecules) (Han, X. et al., 2008). In peptides this leads to backbone 
fragmentation of the C–N bond resulting in a series of b- and y-fragment ions (Chen, G. and 
Pramanik, 2009; Han, X. et al., 2008). The mass difference between consecutive ions in the 
same series can be used to determine the identity of the consecutive amino acids except 
leucine and isoleucine, since they are isobaric (Chen, C.-H. W., 2008). 
The information produced by the mass spectrometer, lists of mass-to-charge (m/z) 
values and their intensities, can be processed and compared with lists generated from 
‘‘theoretical’’ fragmentation of a peptide (Wysocki et al., 2005; Yates, 2000). 
Shotgun proteomics, also known as discovery proteomics, is a universally and 
successfully used proteomic method for identifying proteins in complex mixtures. In this 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 - Principle of a time-of-flight mass analyzer. A beam of ions from a continuous ionization 
source, such as ESI, are transmitted between the orthogonal ion extraction plate and grid. A segment of the 
beam is then pushed into the field-free region by a pulse in the orthogonal direction. Adapted from (Dass, 
[s.d.]).  
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method, the enzymatically digested protein sample is analyzed by LC–MS/MS operated in data-
dependent acquisition or information dependent acquisition (IDA) mode (Liu, Hüttenhain, 
Collins, et al., 2013). In this mode, peptide fragmentation in the mass spectrometers is guided 
by the abundance of peptide ions or so-called precursor ions detected in a survey scan (Liu, 
Hüttenhain, Collins, et al., 2013). Experimentally, the IDA function will acquire a TOF-MS 
survey scan and search for the most intense ions in the spectrum. Ions which intensities exceed 
the threshold level are selected by the first mass analyzer and subjected to collision-induced 
dissociation. A high-resolution mass spectrum of the fragment ions is collected with the TOF 
analyzer (Figure 2.5) (Aguilar, 2004). The fragment ion spectra along with the mass of the 
precursor ion are then searched against isolation protein database to infer the peptide 
sequence and protein identity (Liu, Hüttenhain, Collins, et al., 2013). 
The confidence in protein identification is increased with the number of distinct amino 
acid sequences identified. Therefore, proteins are normally categorized into different priority 
group depending on whether they have only one or multiple unique sequences of the required 
peptide identification confidence (Wang et al., 2008).  
 
Figure 2.5 - Schematic description of a typical “shotgun” experiment in a Q-TOF instrument. 
The instrument cycles between 2 different scan modes. (A) In the first mode all ions are transmitted through 
the instrument and detected after the TOF analyzer, the detector can be subsequently used for parent ion 
determinations. The derived MS spectrum is analyzed using simple rules (intensity, charge state and whether 
the ion has been fragmented before). Ions which pass these simple rules are then isolated and fragmented. (B) 
In MS/MS mode, specific masses are isolated in the first quadrupole and fragmented in the second quadrupole. 
All of the fragment ions are recorded in the analyzer and a MS/MS spectrum is generated, which can be used 
for peptide identification (Tate et al., 2013). 
 
A 
B 
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Some strategies have been developed that rely on neither detection nor knowledge of 
the precursor ions to trigger acquisition of fragment ion spectra (Gillet et al., 2012). These 
include data independent acquisition (DIA) which does not select ions to be fragmented based 
on information in the precursor ion scan. The aim of this approach is to fragment the entire 
set of precursor ions in the visible range of the mass spectrometer (Tate et al., 2013).  
DIA provides a unique feature, namely a complete digital MS/MS record of all compounds 
that are detectable within the sample. This record allows a hypothesis to change during a 
biological study, and hence data from libraries can be used to probe samples for proteins which 
were not originally targeted or identified within a sample (Tate et al., 2013). 
Improvements in MS instrument design allowed the introduction of more robust 
quantitative MS-based techniques for handling the relatively low amount of protein available 
for neuroproteomic studies (Craft et al., 2013). 
In this project a label free quantitative mass spectrometry approach will be used, 
specifically, a SWATH-MS analysis (Figure 2.6), a data-independent acquisition technique. 
  
 
 
 
 
 
 
In a label-free experiment, quantification is achieved through comparison of peak areas 
obtained for an analyte under two or more biological conditions (Vowinckel et al., 2013). 
SWATH (sequential window acquisition of all theoretical fragmentation spectra) allows 
both relative and absolute protein levels to be measured in a biological sample (Craft et al., 
2013). It is a method in which data are acquired on a fast, high resolution Q-TOF instrument 
(Liu, Hüttenhain, Surinova, et al., 2013). SWATH acquisition consists of the sequential selection 
of sequential precursor ion mass windows (normally repeatedly cycle through 32 consecutive 
 
 
Figure 2.6 - Schematic representation of SWATH DIA. Here, the first mass selection quadrupole 
isolates and transmits ions in a defined window (25 Da, swaths) which will contain a number of different parent 
ions. This mixture of ions is fragmented in a collision cell by collision induced fragmentation and transmitted 
to the TOF analyzer where all product ions are measured at resolution 10 p.p.m. The high resolution of MS 
spectra ensures the specificity of peptide identification (adapted from (Ong, Foster and Mann, 2003)). 
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25 Da precursor isolation windows (swaths)) (Zhang, Fanglin et al., 2014), fragmentation of all 
precursor ions selected in each window within the 400 to 1200 m/z precursor range and 
recording of the resulting composite fragment ion spectra (Gillet et al., 2012; Liu, Hüttenhain, 
Collins, et al., 2013; Tate et al., 2013; Vowinckel et al., 2013).  
Using such scans, the link between the fragment ions and the precursors from which 
they originate is lost, increasing the complexity of the analysis of the acquired data sets. 
Consequently, the composite spectra generated by DIA methods have been mainly analyzed 
with the standard database searching tools developed for IDA, either by searching the 
composite fragment ion spectra directly or by searching pseudo fragment ion spectra 
reconstituted post acquisition based on the co-elution profiles of precursor ions (from the 
survey scans) and of their potentially corresponding fragment ions (Gillet et al., 2012). 
This acquisition mode essentially converts the peptides in a physical sample into a high-
resolution digital map consisting of fragment ions spectra derived from the fragmentation of 
all precursor ions present in the sample in a predetermined mass to charge window and at a 
certain time (Liu, Hüttenhain, Collins, et al., 2013). Quantification is conducted based on the 
peak areas of extracted ion chromatograms (XIC), which are computationally reconstituted 
from the merged spectra on the basis of both experimental and in silico generated spectral 
information (Vowinckel et al., 2013).
  
OBJECTIVES 
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3. OBJECTIVES 
 
Psychotic medication is the main treatment for schizophrenia patients, however their 
long-term mechanisms of action are not completely understood. Thus, the proteomic 
alterations observed in SCZ patients subjected to chronic medication act as a confounding 
factor with alterations from the disease alone. This distinction between pharmacological and 
disease related changes is crucial to reveal the etiology and pathophysiological mechanisms of 
the disease.   
Therefore, the aim of the present study was the identification of proteomic changes in 
prefrontal cortex tissue from mice chronically treated with three commonly prescribed 
psychotropic drugs namely, haloperidol, clozapine and citalopram.  
The identification of the proteomic alterations of these drugs will help to provide a 
better understanding of drug action, leading to a better comprehension of their efficacy and 
adverse effects, as well as, to gain new insights into the protein signaling pathways that they 
influence, in order to better combine and potentiate the outcomes of the therapies or even 
to discover new therapeutic targets. 
To accomplish this goal, the following tasks were proposed: 
 
1) Optimization and evaluation of the subproteome fractionation procedure;  
2) Subproteome fractionation of the prefrontal cortex tissue from mice treated with the 
psychotropic drugs mentioned above; 
3) Proteomic identification of medication-associated changes using a label free 
quantitative mass spectrometry approach (SWATH analysis). 
 
  
EXPERIMENTAL PROCEDURES 
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4. EXPERIMENTAL PROCEDURES 
 
4.1. ANIMALS AND DRUGS ADMINSTRATION  
 
Animals’ samples were kindly prepared in Dra. Graça Baltazar’s lab with the help of 
Sandra Rocha (University of Beira Interior, Covilhã). 
Young black male C57BL/6J mice were purchased from Charles River, Laboratories 
International, Inc. (Spain). They were divided into four groups, 6 animals per group. Each animal 
weighed around 20-25 g with access to food and water ad libitum. 
After a habituation phase in which animals got used to the injection needle they were 
chronically treated for four weeks. The animals were injected, via intraperitoneal with 
clozapine, citalopram and haloperidol at a dose of 20 mg/Kg, 10 mg/Kg and 1 mg/Kg, 
respectively. All drugs were dissolved by diluting of stock on 0.13% HCl 5M with 0.9% NaCl. 
An additional group was treated with vehicle only (saline solution) and represent the control. 
The age of animals at start of the habituation phase was 10 weeks and mice were injected daily 
for 30 days.  
After the drug treatment, animals were weighed and anesthetized with a mixture of 
ketamine (100 mg/Kg) and xylazine (10 mg/Kg) 24 hours after the final injection. 
Animals were sacrificed and their brains were removed and dissected. Tissue was 
dissected bilaterally and prefrontal cortex was collected. TEAB 0.5 M (triethylammonium 
bicarbonate buffer) with phosphatases and proteases inhibitors (Roche) was added to each 
tube. All samples were stored at -80ºC until use. 
 
4.2. SUBPROTEOME FRACTIONATION (Membrane Protein Enrichment) 
  
To each microcentrifuge tube containing the prefrontal cortex, 1 mL of Tris 0.05 M 
(tris(hydroxymethyl)aminomethane) with phosphatases and proteases inhibitors was added. 
The brain tissues were homogenized with ultrasonication (Vibra Cell 130 watts, Sonics) with 
the 3 mm probe for 30 seconds at 40% amplitude with 1 second cycles and for 15 seconds at 
50% with 1 second cycles. Afterwards the samples were centrifuged (Centrifuge 5417R, 
Eppendorf) at 5,000×g for 5 minutes at 4ºC. The supernatants were saved in a new 
microcentrifuge tube and 500 µL of Tris 0.05 M with phosphatases and proteases inhibitors 
were added to the pellets. Pellets were homogenized with the 3 mm probe for 30 seconds at 
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40% with 1 second cycles, and centrifuged as mentioned before. The supernatants were saved 
with the rest of the samples and the volume was adjusted to 2 mL with Tris-buffer. The new 
pellets (tissue debris) were discarded. 
Then the volume corresponding to 30 mg of brain tissue were transferred to 
ultracentrifuge tubes and the volume was adjust at 2 mL with Tris-buffer. The rest of the 
sample was kept at -80ºC. 
An ultracentrifugation (OptimalTM L-100 XP, Beckman Coulter) at 144,000×g for 1hour 
at 4ºC was performed and the supernatant (soluble fraction) was taken to a centrifuge tube. 
To the pellet samples (membrane enriched fraction) 750 µL of TEAB 0.5 M were added and 
the pellet was dissolved using the sonicator with the 3 mm probe for 15 seconds at 40%, once, 
after this the pellet was unstacked from the ultracentrifuge tube and homogenized again, 30 
seconds at 40% amplitude with 1 second cycles and 30 seconds at 50% amplitude with 1 second 
cycles, this step was repeated until total dissolution.   
 
4.3. PROTEIN PRECIPITATION 
 
Cold acetone (-20 °C) in a volume ratio of 1:6 (sample:acetone) was added to each 
soluble samples and methanol 1:4 (sample:methanol) was added to each membrane samples. 
The sample tubes were inverted several times to mix and incubated at -80ºC overnight. All 
samples were centrifuged (Centrifuge 5810 R, Eppendorf) at 3,220×g at 4ºC during 20 minutes 
and 150 µL of TEAB 0.5 M were added to the samples pellet, further dissolved using the 3 mm 
probe for 10 seconds at 20% amplitude with 1 second cycles twice. The homogenized samples 
were transferred to a microcentrifuge tube and the volume was adjusted at 200 µL. All samples 
were stored at -80ºC until posterior use.  
 
4.4. PROTEIN QUANTIFICATION (2-D Quant Kit)  
 
The 2-D Quant Kit (GE Healthcare) was used to determine the protein concentration 
in samples. Bovine serum albumin (BSA) was used as standard and the assay was performed 
following the manufacturer protocol. Shortly, the standards and the samples were first 
precipitated and then resuspended in a copper solution. The copper binds to the protein and 
the unbound copper is measured with a colorimetric agent.  Samples were incubated at room 
temperature for 15 minutes. The samples’ absorbance was measured at 480 nm on a 
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Microplate Spectrophotometer (PowerWave XS, BioTek). Using the results, a calibration 
curve was obtained and the protein concentration was interpolated from it. 
 
4.5. EVALUATION OF THE SUBPROTEOME FRACTIONATION  
 
4.5.1. SDS-PAGE (Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis)  
 
Three soluble pools and three membrane pools were made using eight samples by pool 
(5 µg of protein of each sample). The eight samples were obtained from each subproteome 
fractionation procedure that was performed 3 times. For this procedure 30 µg of protein of 
each pool were denatured with the addition of Laemmli Sample Buffer 6× [0.35 M Tris-HCl, 
pH 6.8 with 0.4% SDS (v/v), 30% glycerol (v/v), 12% SDS (w/v), 9.3% DTT (w/v), 0.01% 
bromophenol blue (w/v) and 4 M NaCl] to a 1× final concentration and boiled at 60ºC for 10 
minutes.  
Green Fluorescence Protein (GFP) was denatured with the addition of Laemmli Sample 
Buffer 6× [0.35M Tris-HCl, pH 6.8 with 0.4% SDS (v/v), 30% glycerol (v/v), 10% SDS (w/v), 
9.3% DTT (w/v) and 0.01% bromophenol blue (w/v)]  to a 1× final concentration and boiled 
at 95ºC for 5 minutes. To each sample 0.84 ng of GFP were added and used to normalize the 
western blot procedure.   
The samples were electrophoretically separated in a pre-cast stain-free 4-20% SDS-
polyacrylamide gel (Bio-Rad) using a Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad). 
The profile of the gel was then visualized by ultraviolet light (GelDoc XR, BioRad). 
The rest of each pool (10 µg) were added to made a new soluble pool and membrane 
pool, thus 30 µg of protein of each pool were denatured in the same conditions described 
above for GFP and were electrophoretically separated on a 12.5% SDS-polyacrylamide gel 
(Bio-Rad) using a Mini-PROTEAN Tetra Electrophoresis System. 
 
4.5.2. Immunoblot Detection 
 
Proteins were transferred to Trans-Blot® TurboTM Midi-size polyvinylidene fluoride 
(PVDF) membranes (Bio-Rad) using a Trans-Blot® Transfer System (Bio-Rad). The following 
programs were used to transfer the pre-cast stain-free 4-20% and 12.5% SDS-polyacrylamide 
gels: 2.5 A constant; up to 25 V during 10 min and up to 1.0 A; 25 v constant during 30 min, 
respectively. After the transference, the membranes were blocked for 1 hour at room 
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temperature (RT) with 5% (w/v) skimmed milk powder dissolved in PBS with 0.1% (v/v) 
Tween-20 (PBS-T) (Bio-Rad).  
Membranes were then incubated with primary antibodies against NMDA C-20 (1:500) 
(115 kDa), DJ1 C-16 (1:200) (25 kDa) [Santa Cruz Biotechnology, Inc. (sc-1467)] and GFP 
(1:500) (27 kDa) (SicGen AB0020-500) in 5% (w/v) skimmed milk powder dissolved in PBS-T, 
overnight at 4ºC followed by 1 hour at RT. Primary antibodies are removed and membranes 
were washed with PBS-T (3 times for 15 min under agitation). Subsequently, the membranes 
were incubated 1 hour at RT with the secondary antibody conjugated with alkaline 
phosphatase (anti-goat (1:6000), from Jackson ImmunoResearch Laboratories), in 5% (w/v) 
skimmed milk powder dissolved in PBS-T, followed by three washes as above. Each membrane 
was incubated for a maximum period 5 minutes, to observe protein-immunoreactive bands, 
with “Enhanced Chemifluorescence (ECF) detection system” (GE Healthcare) and visualized 
in a Molecular Imager FX System (Bio-Rad) (filter A – 530 nm; laser- 488 nm). The Quantity 
One® software (Bio-Rad version 4.6) was used to adjust the volumes (total intensities in a 
given area with global and local background subtraction for each band and with global 
background subtraction for each lane). 
Thereafter, the membranes incubated with NMDA antibodies were incubated for 15 
min with a stripping solution [0.2 M Glycine, 0.1% SDS and 1% Tween-20] to remove the 
labeling of the antibodies and the procedure was repeated with new antibodies Anti-VDAC-1 
N-18 (1:500) (33 kDa) [Santa Cruz Biotechnology, Inc. (sc-8828)]. 
 
4.6. SAMPLE PREPARATION FOR LC-MS 
  
For each sample group (control, haloperidol, citalopram and clozapine), 20 µg of protein 
were pooled together for the library identification (total of mg of proteins from the 6 animals). 
These pools (120 µg of protein with 2.1 µg of GFP) and 80 µg of each sample (with 2.1 µg of 
GFP), for the SWATH analysis, were denatured with Laemmli Sample Buffer 6× to a 1× final 
concentration and boiled at 95ºC during 5 minutes. In order to promote the cysteine 
alkylation, acrylamide [40% acrylamide/bis solution (Bio-Rad)] was added to the samples (2 µL 
of acrylamide per 30 µL of sample). The samples were loaded in a pre-cast 4-20% SDS-
polyacrylamide gel and electrophoretically resolved during 15 minutes at 110 v using a Mini-
PROTEAN Tetra Electrophoresis System. The pools were separated in 3 different wells in the 
gel while individual samples were separated into two wells. 
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The gel was then stained with Coolloidal Coomassie Blue. Briefly, after electrophoresis, 
the gel was washed with deionized water and immersed in staining solution [10% (v/v) of 85% 
solution of phosphoric acid, 10% (w/v) ammonium sulphate, 20% (v/v) methanol]. The 
Coomassie powder was added to the solution with a strainer to allow the formation of 
colloidal particles under agitation and allowed to stain. After that, successive washes were 
made and the gel was maintained in water. 
The top of each gel lanes was sliced into 9 bands of equal size using a disposable 
GridCutter (2 mm × 7 mm lanes, 25 rows, 1 column). Then the bands were grouped three by 
three, sliced into smaller pieces, and transferred to microcentrifuge tubes with 600 µL of ultra-
pure water (VWR) to prevent band pieces to dry. To destain the gel pieces the water was 
removed and 1 mL of the destaining solution (50 mM ammonium bicarbonate and 30% 
acetonitrile) was added. The tubes were placed in a thermomixer (Comfort, Eppendorf) at 
850 rpm for 15 minutes at 25°C. The solution was removed and 1mL of water was added and 
tubes were shaken in the thermomixer at 850 rpm for 10 minutes at 25ºC. If the gels pieces 
remained blue this destaining step was repeated. Afterwards, the water was removed and the 
gel pieces were dehydrated on the Concentrador Plus (Eppendorf) for 1 hour at 60°C. When 
the gel pieces were dehydrated, sufficient volume of trypsin (Roche) (15 ng/µL in 10 mM 
ammonium bicarbonate) was added until all dried gel pieces were covered and incubated 
during 15 minutes, on ice, to rehydrate the gel. After this period, 10 mM ammonium 
bicarbonate (final concentration of trypsin 10 ng/µL) was added to cover gel pieces again, and 
incubated overnight (16 hours) at room temperature in the dark to perform the in-gel 
digestion. After digestion, the tryptic solution (containing trypsin and some peptides) was 
collected to Lobinding® microcentrifuge tubes (Eppendorf). The pool samples were collected 
to three different tubes to separate the top, middle and bottom of the gel and the other 
samples were collected each for individual tubes. The remaining peptides were extracted by 
adding solutions with an increase concentration of acetonitrile (ACN), thus 100 µL of 30%, 
50%, and 98% of ACN in 1% formic acid (FA) were added. After the addition of each extract 
solution the tubes were placed in the thermomixer at 1050 rpm for 15 minutes at 25ºC and 
each solution was collected to the tube containing the initial tryptic solution. The peptide 
mixtures were concentrated on the Concentrador Plus (Eppendorf) at 60ºC, resuspended to 
a final volume of 100 µL in a solution of 2% ACN and 1% FA, and sonicated on a Sonics 750 
W using a cup-horn (2 min with 1 sec on 1 sec off cycles at 20% of amplitude). At this point 
the peptide extraction was complete and the peptides were prepared to be desalted.  
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4.7. C18 PEPTIDE CLEAN UP  
 
Peptides were cleaned/desalted using C18 Bond Elut OMIX solid phase extraction 
pipette tips (Agilent technology). Briefly, 200 µL of 50% ACN were used to hydrate the tip 
columns, to equilibrate them 300 µL of 2% ACN with 1% FA solution were added. The 
peptides were loaded into the column and this step was repeated five times followed a wash 
step with 100 µL of 2% ACN with 1% FA solution (this wash is saved until the analysis of the 
peptides is performed). Peptides were eluted to new tubes with 400 µL of 70% ACN and 0.1% 
FA and eluates were concentrated using the Concentrator Plus at 60 °C. Individual sample 
volume was adjusted to 30 µL and pool samples to 20 µL in a solution of 2% ACN and 0.1% 
FA with Indexed Retention Time (iRTs) (BIOGNOSYS) and sonicated at 20% of amplitude for 
2 minutes (1 second on 1 second off cycle), centrifuged at 14,000×g for 5 minutes and the 
supernatants were transferred into vials for posterior LC-MS/MS analysis. 
 
4.8. PROTEIN IDENTIFICATION AND QUANTIFICATION  
 
Digested proteins were analyzed on a hybrid quadrupole time-of-flight mass 
spectrometer (Triple TOF™ 5600 System; ABSciex). Firstly, peptides were separated by liquid 
chromatography (NanoLC Ultra 2D, Eksigent) on a ChromXP™ C18 reverse phase column 
(300 μm ID × 15 cm length, 3 μm particles, 120 Å pore size, Eksigent) at 5 µL/min. Peptides 
were eluted into the mass spectrometer in a linear gradient for 45 min with an acetonitrile 
gradient in 0.1% FA (from 2% to 30%), using an electrospray ionization source (DuoSpray™ 
Source, ABSciex) in positive mode. Using the same chromatographic conditions, the pool 
samples were analyzed by information dependent acquisition to create the library identification 
and the rest of the soluble samples by information independent acquisition. Rolling collision 
was used with a collision energy spread of 5. The volume of each poll sample (5 µL) was 
analyzed using classical shotgun data acquisition. The mass spectrometer was set for 
information dependent acquisition scanning full spectra (350-1250 m/z) for 250 ms, only for 
the 30 most intense ions. Candidate ions with a charge state between +2 and +5 and counts 
above a minimum threshold of 70 counts per second were isolated for fragmentation and 
performed one MS/MS (100-1500 m/z for 100 ms) before adding those ions to the exclusion 
list for 15 seconds (mass spectrometer operated by Analyst® TF 1.6, ABSciex).  In quantitative 
analysis by acquisition in SWATH mode, 5 µL of the volume of each soluble sample were used.  
In the SWATH analysis the same chromatographic conditions as in the IDA run described 
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above were used. For SWATH-MS–based experiments, the mass spectrometer was operated 
in a looped product ion mode. The instrument was specifically tuned to allow a quadrupole 
resolution of 25-m/z mass selection. Using an isolation width of 26 m/z (containing one m/z 
for the window overlap), a set of 29 overlapping windows was constructed covering the 
precursor mass range of 350–1100 m/z. A 50 ms survey scan was acquired at the beginning of 
each cycle for instrument calibration and SWATH MS/MS spectra were collected from 100–
1500 m/z for 100 ms resulting in a cycle time of 3.15 s from the precursors ranging from 350 
to 1100 m/z. The collision energy for each window was determined according to the 
calculation for a charge 2+ ion centered upon the window with a collision energy spread of 
15. 
 
4.9. IDA AND SWATH DATA FILE ANALYSIS   
 
To the IDA analysis the pools’ files were combining by condition (control, haloperidol, 
citalopram and clozapine) and peptide identification was performed using Protein Pilot 
software v5 (ABSciex). The parameters for search were the following: Uniprot_SwissProt 
database for mouse (last update in July 2014); trypsin digestion, acrylamide as cysteine 
alkylating reagent, thorough ID search effort, and 0.05 unused ProtScore (10% confidence 
score) as detected protein threshold. Data analysis was based on an independent False 
Discovery Rate analysis (FDR) using the target-decoy approach. Positive identifications were 
considered when proteins present 95% confidence (5% local FDR) with more than one peptide 
hit with individual confidence above 95%. When a protein was identified with a single peptide, 
an Unused above 1.3 was considered as positive identification or the peptide has to present 
an individual confidence above 95% and a minimum sequence tag of 3 amino acids (4 
consecutive peaks in the MS/MS spectrum). The reverse proteins and peptides, as well as, the 
peptides with zero contribution were removed.  
Combining all files from the IDA experiments led to the creation of a library of precursor 
masses and fragment ions, that was used for subsequent SWATH processing. Search 
parameters used were the same for the pools’ IDA with the addition of GFP protein and iRTs 
peptides to the database.  
The protein quantification was performed using Peak View Software v2.1 (ABSciex). The 
IDA library was imported to the software along with the swath files. Peptides were selected 
automatically from the library using the following criteria: (i) the unique peptides for a specific 
targeted protein were ranked by the intensity of the precursor ion from the IDA analysis as 
estimated by the ProteinPilot software, and (ii) Peptides that were shared between different 
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protein entries/isoforms were excluded from selection. Up to 15 peptides were chosen per 
protein, and SWATH quantitation was attempted for all proteins in library files that were 
identified below 5% local FDR from ProteinPilot searches.  
According to the criteria described in (Lambert et al, 2013)  target fragment ions, up to 
5, were automatically selected and peak groups were scored. For the latter the criteria are 
the following: each target fragment ion was scored based on the retention time adjustment, 
peak width overlap, peak intensity ratio, correct isotopic state, m/z error and MS/MS score. 
The individual peak group scores were combination of all subscores (scores from fragment 
ions) and the peak group with the best score was taken forward. Peak group confidence 
threshold was determined based on a FDR analysis using the target-decoy approach and 1% 
extraction FDR threshold was used for all the analyses. 
The peak areas of the target fragment ions of peptides were extracted across the 
experiments using an extracted-ion chromatogram (XIC) window of 5 minutes with a 0.02 Da 
width.  
Peptide features (i.e., peptides in a given charge state) that met the 1% FDR threshold 
at least in 3 replicates for a given condition were retained, as well as, peptides that have 
contribution for all the experiments. In order to estimate the protein levels, all the transitions 
from all the peptides for a given protein were summed. Protein levels were normalized using 
GFP protein as internal standard.  
 
4.10. SOFTWARE TOOLS FOR PROTEINS ANALYSIS  
  
Venn diagrams were used to compare the number of proteins that are shared or unique 
among the four groups.  
The Venn diagram tool (http://bioinformatics.psb.ugent.be/webtools/Venn/) from 
Bioinformatics & Evolutionary Genomics was used. The lists containing the proteins from the 
desired conditions to be compared were uploaded and the selected output was symmetric 
Venn diagrams. The tool generates a Venn diagram of the inserted conditions and a text file 
containing the accession numbers of the analyzed proteins and the distribution of these 
proteins within the different conditions compared.  
GO enrichment analysis was performed for each list of proteins identified in each 
condition, using the web-based application Gene Ontology enRIchment anaLysis and 
visuaLizAtion tool – GOrilla (http://cbl-gorilla.cs.technion.ac.il/). GOrilla helps to identify and 
visualize enriched GO terms in genes or proteins lists. The output of this analysis is visualized 
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as a hierarchical structure, using a representation with color-coding that reflects the 
enrichment degree based on the p-value. All the analyses were done for the Mus musculus, in 
the single ranked list of genes running mode and based on cellular component, molecular 
function and biological process. Diagrams were exported and presented as results. 
PANTHER Classification System (http://www.pantherdb.org/tools/) was performed for 
each list of proteins that were considered altered. This tool creates map lists of molecular 
function and biological process categories, as well as cell component. All the analyses were 
done for the Mus musculus, and the results were viewed in pie chart based in their functional 
classification - biological process. 
UniProt (http://www.uniprot.org/) is the universal protein resource, a central repository 
of protein data created by combining the Swiss-Prot, TrEMBL and PIR-PSD databases. This 
software was used to identify and to provide information about the proteins that were found 
changed comparing with the control condition, using the accession number of them. 
 
4.11. STATISTICAL ANALYSIS 
Statistical analysis of results from western blot procedure was performed using 
GraphPad PRISM® v5, data normality was tested using Mann-Whitney Test and statistical 
evaluation was performed with a one-way ANOVA analysis. The results were reported as 
statistically significant when p < 0.05. Data were expressed as mean ± standard error of the 
mean (S.E.M.).   
SPSS (Statistical Package for the Social Sciences) version 18 (IBM®) was used to identify 
the proteins that were altered by the drugs. An outlier analysis was performed and the control 
data were compared with each drug group (haloperidol, clozapine and citalopram). The results 
were reported as statistically significant when p < 0.05 and/or proteins which are outside a 
1.5 fold factor were considered as being changed between the control and the drug group.  
 
 
  
RESULTS AND DISCUSSION 
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5. RESULTS AND DISCUSSION  
 
Schizophrenia is likely to be a multifactorial disorder, consequence of alterations in gene 
and protein expression, since the neuro-development together with environmental factors 
will trigger the establishment of the disease (Martins-de-Souza, 2011). In the post-genomic era, 
proteomics has emerged as a promising strategy for revealing disease and treatment 
biomarkers as well as a tool for understanding the mechanisms of schizophrenia pathobiology 
(Martins-de-Souza, 2011). 
The analysis of the pharmacological profile of antipsychotic drugs or neurochemical 
consequences of antipsychotic treatment has been widely used to understand the 
pathophysiology of schizophrenia (Park, J. et al., 2012b). Considering that SCZ is a brain 
disorder, the study of brain tissue seems a natural path to follow for the understanding of its 
pathobiology. The prefrontal cortex is one of the brain regions that have been strongly 
correlated with SCZ (Martins-de-Souza, 2011), and for this reason it was the tissue studied in 
this project. 
In this project four animals groups were studied: control, haloperidol, citalopram and 
clozapine. The control group represents the mice that were not injected with the drugs and 
the haloperidol, citalopram and clozapine groups, the mice that were injected with the 
respective drugs (see Experimental procedure 4.1). In each group there are six mice that were 
the biological replicates, the samples CT1, CT2, CT3, CT4, CT5, CT6 are mice from the 
control group; the samples HA1, HA2, HA3, HA4, HA5, HA6 are from the haloperidol group; 
the samples CI1, CI2, CI3, CI4, CI5 and CI6 are from the citalopram group; and the samples 
CL1, CL2, CL3, CL4, CL5 and CL6 are from the clozapine group.   
A major difficulty with proteomic approaches is the extraordinarily high protein 
complexity of biological samples. Likely more than 100,000 different protein isoforms exist in 
a cell. This complexity requires the prefractionation of samples prior to protein analysis in 
order to make low-to-medium abundant proteins detectable (Schindler et al., 2006). In order 
to simplify the prefrontal cortex samples, a membrane protein enrichment was performed 
(see Experimental Procedure 4.2). In this procedure, an ultracentrifugation step was sufficient 
to separate membrane from soluble proteins (see Supplementary Subchapter 8.1). Only the 
soluble fractions were analyzed by mass spectrometry in this project.  
After the subproteome fractionation procedure the proteins in the soluble fraction were 
precipitated with acetone and the proteins in membrane samples were precipitated with 
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methanol (see Experimental Procedure 4.3), once these two solvents proved to be most 
appropriate for the precipitation of the different fractions (see Supplementary Subchapter 8.2).  
 
5.1. PROTEIN QUANTIFICATION  
The quantification of the protein in each sample was performed using the 2D-Quant Kit 
(see Experimental Procedure 4.4). The quantification of protein was essential to determine 
the volumes that were used in subsequent analysis, so that the amount of protein in each well 
was the same. The table 5.1 showed the protein concentration (mg/mL) and the total amount 
of protein (mg) of each sample.  
 
Table 5.1: Protein concentration of samples obtained by 2-D Quant Kit. Protein concentration and the 
total amount of each sample was calculated. [] - concentration of proteins. CT1/CT2/CT3/CT4/CT5/CT6- soluble 
and membrane protein fraction from Control group obtained after the subproteome fractionation; 
HA1/HA2/HA3/HA4/HA5/HA6- soluble and membrane protein fraction from Haloperidol group obtained after 
the subproteome fractionation; CI1/CI2/CI3/CI4/CI5/CI6- soluble and membrane protein fraction from 
Citalopram group obtained after the subproteome fractionation; CL1/CL2/CL3/CL4/CL5/CL6- soluble and 
membrane protein fraction from Clozapine group obtained after the subproteome fraction. 
 
The total amount of protein in the soluble and membrane samples range between 0.39-
0.86 mg and 0.72-1.13 mg, respectively. According (Schindler et al., 2006) the class of 
membrane protein are less abundant in a cell, they are assumed to constitute about 20–30% 
of cellular proteins. Nevertheless, the amount of protein in membrane samples were higher 
than the soluble samples, this is due to the fact that during the membrane enrichment 
procedure there is the accumulation of membrane proteins but also cytoskeletal proteins in 
Soluble 
Samples 
[] 
(mg/mL) 
Total 
amount 
(mg) 
Soluble 
Sample 
[] 
(mg/mL)
Total 
amount 
(mg) 
Membrane 
Samples  
[] 
(mg/mL)
Total 
amount 
(mg) 
Membrane 
Samples  
[] 
(mg/mL) 
Total 
amount 
(mg) 
CT1  2.91  0.58  CI1  2.6  0.52  CT1  5.09  1.02  CI1  4.28  0.86 
CT2  2.24  0.45  CI2  3.42  0.69  CT2  3.99  0.8  CI2  4.3  0.86 
CT3  3.22  0.64  CI3  4.29  0.86  CT3  4.63  0.93  CI3  5.51  1.1 
CT4  3.07  0.61  CI4  4.02  0.8  CT4  3.95  0.79  CI4  5.02  1 
CT5  1.97  0.39  CI5  1.98  0.4  CT5  3.88  0.78  CI5  3.64  0.73 
CT6  1.97  0.39  CI6  2.03  0.41  CT6  3.79  0.76  CI6  3.59  0.72 
HA1  2.77  0.55  CL1  2.19  0.44  HA1  4.81  0.96  CL1  3.84  0.77 
HA2  3.21  0.64  CL2  2.77  0.55  HA2  4.88  0.98  CL2  4.56  0.91 
HA3  3.15  0.63  CL3  3.29  0.66  HA3  5.26  1.05  CL3  5.14  1.03 
HA4  3.71  0.74  CL4  3.64  0.73  HA4  4.9  0.98  CL4  5.07  1.01 
HA5  2.91  0.58  CL5  2.13  0.43  HA5  5.31  1.06  CL5  3.73  0.75 
HA6  2.6  0.52   CL6  2.47  0.49  HA6  4.97  0.99  CL6  3.85  0.77 
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the membrane fraction,  making the amount of protein content greater in the membrane 
fraction than in the soluble fraction.  
 
5.2. EVALUATION OF THE SUBPROTEOME FRACTIONATION 
PROCEDURE 
In order to evaluate the subproteome fractionation procedure, the samples were pooled 
and resolved in a pre-cast stain-free 4-20% SDS-polyacrylamide gel, and the profile of the gel 
was visualized by ultraviolet light (figure 5.1). The soluble pools (PS1, PS2 and PS3) and 
membrane pools (PM1, PM2 and PM3) were prepared adding the soluble and membrane 
samples that were processed in the same ultracentrifugation step, respectively (see 
Experimental Procedure 4.5.1).  
 As it can be observed in figure 5.1, the pooled samples of the soluble fractions present 
a similar profile among themselves. The pooled samples of the membrane fractions also 
present a similar profile among themselves but different comparing with the soluble samples. 
For instance, the first intense band in the soluble samples (black box) corresponds to a less 
intense band in the membrane samples, as well as, the first intense band in the membrane 
samples (white box) corresponds to a less intense band in the soluble samples. In the upper 
part of the gel a band with high intensity can be noted in the membrane samples, which 
represents proteins with higher molecular weight (which are usually associated to membrane 
proteins), while in the soluble samples the most intense bands are observed in the bottom of 
the gel, which correspond to proteins with low molecular weight (possibly soluble proteins). 
 Accordingly, it is possible to conclude that there was a separation of certain subsets of 
proteins during the subproteome fractionation procedure which cause the different profiles 
between the membrane and soluble samples.  
 To accomplish the same goal described above, pooled samples were analyzed by western 
blot (see Experimental Procedure 4.5.2), thus, some proteins were used as potential 
membrane and soluble markers to confirm the subproteome fractionation procedure.   
 Primarily, the PSD-95 (postsynaptic density protein 95) and GAPDH (Glyceraldehyde 3-
phosphate dehydrogenase) proteins were used as membrane and soluble markers, (as widely 
referred in the literature) respectively, but as the PSD-95 is not a transmembrane protein and 
GAPDH was observed in all cellular compartments the results were not conclusive (see 
Supplementary subchapter 8.3.1), consequently other proteins were chosen as fractionation 
on enrichment markers. 
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Figure 5.1: Evaluation of the subproteome fractionation procedure. PS1/PS2/PS3- pool of the soluble 
samples that were performed in the first, second and third days of ultracentrifugation, respectively; 
PM1/PM2/PM3- pool of the membrane samples that were performed in the first, second and third days of 
ultracentrifugation, respectively; SB- sample buffer. 
   
 
 NMDA (N-methyl-D-aspartate) receptor is a specific type of ionotropic glutamate 
receptor involved in synaptic plasticity and memory (Marti et al., 1993). During excitatory 
neurotransmission, presynaptic release of glutamate activates glutamate receptors in the 
postsynaptic membrane, resulting in the generation of an excitatory postsynaptic potential 
(Conti, 1997; Zito, 2009). The receptor forms a heterotetramer between several subunits, 
primarily comprised of NR1, NR2 and NR3 subunits (Marti et al., 1993). In this project NMDA 
receptor was used as a membrane marker. The denaturation of the NMDA protein in samples 
with Laemmli Sample Buffer 6× to a 1× final concentration and at 95ºC for 5 minutes was 
insufficient, once the protein did not enter in the gel completely. Which led to the need for a 
protocol optimization (see Supplementary Subchapter 8.3.2). The following denaturation 
condition showed better results for NMDAR detection: addition of Laemmli Sample Buffer 6× 
(with 12% SDS and 4M NaCl) to a 1× final concentration and boiled at 60ºC for 10 minutes 
(see Experimental Procedure 4.5). On the other hand, the GFP protein that was added to the 
samples for data normalization, did not show a good profile with the new denaturation 
condition (see Supplementary Subchapter 8.3.2, supplementary figure 8.9). Therefore, the GFP 
protein had to be denatured separately with the Laemmli Sample Buffer 6×  to a 1× final 
            PS1   PM1   SB  PS2  PM2   SB  PS3  PM3 
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concentration, at 95ºC for 5 minutes and added afterwards to the final samples (see 
Experimental Procedure 4.5). 
 The results obtained from western blot (figure 5.2) showed intense bands with a 
molecular weight corresponding to the NMDAR detection (115 kDa) only in the pools of 
membrane samples, as expected. As previously stated NMDAR is a complex protein and 
although the denaturation conditions were changed and the majority of the protein entered 
into the running gel, an intense smearing in the lane continues to be observed. Therefore, both 
the bands and the lanes were analyzed in Quantity One® software with local subtraction 
background, in order to confirm the results.   
Although the standard deviation (SD) was higher in the analysis of the lanes than in the 
bands, the results were as expected, both analysis (bands and lanes) showed a higher detection 
of NMDAR for the pools of membrane samples (black bars) comparing with the pools of 
soluble samples (white bars), meaning that the NMDAR was found in greater amount in the 
membrane fractions. The same was observed with lower standard deviation using a dot blot 
analysis, and showed a % of coefficient of variation (CV) below 30% in the samples where 
NMDA is supposed to be present (see Supplementary table 8.2). 
Once the NMDA detection always presents an intense smearing throughout the lane, to 
remove any doubt relatively to the previous results, the same procedure was performed using 
VDAC-1 protein as a membrane marker.  
 
 
   
Figure 5.2: Evaluation of the subproteome fractionation procedure. Imunodetection of NMDAR 
as a membrane marker. A- imonodetection of NMDAR as a membrane marker, the GFP protein was used 
SB PS1 PS2 PS3 PM1 PM2 PM3 SB 
NMDAR → 
GFP → 
A B 
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to the normalization of western blot. B- The bands and the lanes of the membrane (A) were analyzed using 
Quantity One® software with local subtraction background and the results represent mean values ± SEM.  
 
The voltage-dependent anion channel (VDAC-1), also known as mitochondrial porin, is 
located in the mitochondrial outer membrane. It functions as a gatekeeper for the entry and 
exit of mitochondrial metabolites, thereby controlling cross-talk between mitochondria and 
the rest of the cell.  VDAC-1 is also a key player in mitochondria-mediated apoptosis (Shoshan-
Barmatz et al., 2010).   
After the detection of NMDAR the same blot membrane was used for the detection 
of  VDAC-1 protein (see Experimental Procedure 4.5). 
 
 
 
 
 
 
Figure 5.3: Evaluation of the subproteome fractionation procedure. Imunodetection of VDAC as 
a membrane marker. The bands of the membrane (A) were analyzed (B) using Quantity One® software with 
local subtraction background and the results represent mean values ± SEM.  
 
As expected, intense bands with a molecular weight corresponding to VDAC-1 protein 
(33 kDa) were observed only in the pool of membrane samples (figure 5.3). The results showed 
higher value of intensity in the membrane samples (black bar) than in the soluble samples, as 
expected, this indicates that, as for NMDAR, the VDAC-1 protein was found in higher amount 
in the membrane fractions.  
In this project the protein DJ-1 protein was used as a soluble marker. DJ-1 is a 
multifunctional protein with anti-oxidant and transcription modulatory activity. It localizes in 
PM3 PS3 SB PM2 PS2 SB PM1 PS1 
VDAC ‐1→ 
A 
B 
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the cytoplasm, mitochondria and nucleus (Junn, 2010). The DJ-1 protein was previous quantified 
by SWATH analysis using the samples that were prepared in Supplementary Subchapter 8.1. 
This protein, although has different localization in the cell, showed a higher amount in soluble 
samples in relation with the membrane samples (data not showed) and a western blot for 
detection of this protein were performed (see Experimental Procedure 4.5). 
 
 
 
 
 
Figure 5.4: Evaluation of the subproteome fractionation procedure. Imunodetection of DJ-1 as a 
soluble marker. The bands of the membrane (A) were analyzed (B) using Quantity One® software with local 
subtraction background. 
 
 The results (figure 5.4) show a higher intensity in the soluble fractions than the 
membrane fractions. Altogether, these results show that the ultracentrifugation results in an 
enrichment of membrane proteins (demonstrated here by NMDAR and VDAC-1) in 
membrane fractions, while the soluble proteins (demonstrated here by DJ-1) were enriched 
in the soluble fractions.   
  
5.3. PROTEIN IDENTIFICATION  
 
In order to verify if the number of proteins in each condition was similar, the six 
replicates in each condition were joined and an identification of the proteins was performed 
by LC-MS/MS (see Experimental Procedure 4.9). The identification of high numbers of proteins 
A 
B 
PS PM MWSB
DJ1 → ←25 kDA 
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is essential to obtain a good IDA library to be used in SWATH analysis, thus a gel digestion 
was performed to the samples, followed by LC-MS/MS and protein identification (the digestion 
procedure was chosen based on the results from different approaches (see Supplementary 
Subchapter 8.4). The total number of proteins that were identified in each condition is very 
similar (figure 5.5). 
 
Figure 5.5: Total number of proteins identified by Mass Spectrometry for each condition. A gel 
digestion was performed to the samples of each condition.  
 
Venn diagrams were used to help to visualize the number of shared and unique proteins 
among different conditions (see Experimental Procedures 4.10). The comparison between the 
pooled samples of control, haloperidol, citalopram and clozapine conditions (figure 5.6) 
revealed that 1190 proteins were shared by all the conditions and 45, 44, 160 and 52 were 
unique proteins identified in control, haloperidol, citalopram and clozapine, respectively.  
Figure 5.6: Venn Diagrams illustrating the number of shared or unique proteins identified by Mass 
spectrometry. There are 1190 common proteins and the combined protein number is 1898. Pool_CT- Pool 
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of control samples; Pool_HA- Pool of Haloperidol samples; Pool_CI- Pool of Citalopram samples; Pool 
Clozapine- Pool of Clozapine samples. 
 
Worth to mention is that the number of unique proteins identified in control, 
haloperidol and clozapine were similar, while in citalopram condition was higher. This fact is 
explained by the increased number of proteins identified by LC-MS/MS (figure 5.5), 
Nevertheless the number of unique proteins identified in the other three conditions was 
similar. 
 
5.3.1. GO Enrichment analysis  
 
An important analysis was to evaluate whether the overall lists of proteins obtained 
were significantly enriched in any particular GO terms based on cellular component, molecular 
function and biological process. For that Gene Ontology enRIchment anaLysis and visualization 
tool (GOrilla) was used (see Experimental Procedures 4.10), which provides a clear view in 
the form of a tree diagram. 
This type of analysis generates large amounts of results and information to be evaluated, 
so considering the enrichment values were formed groups for a simplified visualization of the 
results - “Extracellular Region part” and “Cytoplasmic part of the neuron” in the cellular 
component analysis; “Protein Binding” and “Catalytic activity” in molecular function analysis; 
and “Catalytic Process” and “Carbohydrate catabolic process” in biological process analysis 
(black boxes). For the three analysis (cellular component, molecular function and biological 
process) the diagrams formed for the four conditions (control, haloperidol, citalopram and 
clozapine) were exactly the same, so only the three diagrams for control condition are shown 
(figure 5.7).  
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R E S U L T S  A N D  D I S C U S S I O N  | 55 
 
 
C                                             CT_Biological Process 
 
 
 
 
                                                  
Figure 5.7: Gene Ontology (GO) Enrichment of the identified proteins in the different groups. 
Analysis of the identified proteins in the control group based in cellular component (A) molecular function (B) 
and biological process (C). 
Regarding the cellular component analysis these results indicate that there was an 
enrichment of proteins that belong to the extracellular region part and cytoplasmic part of the 
cell, as expected, once the samples were obtained from the soluble fraction (supernatant) of 
the subproteome fractionation procedure, corresponding to the soluble proteins of the cell. 
The results concerning to the molecular function of the proteins showed an enrichment of 
proteins which had biding and catalytic functions, although this enrichment was not so 
significant with a p < 10-3 to 10-7. In biological process analysis the proteins belong to the 
groups of glycolytic process and carbohydrate catabolic process were the ones with higher 
enrichment. The same results were obtained for the three other conditions and this suggests 
that the identified proteins in the four conditions were very similar.  
 
 
 
 
 
 
Glycolytic Process Carbohydrate 
catabolic process  
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5.4. SWATH ANALISIS 
 
A SWATH-MS analysis was performed to determine which proteins were altered by the 
drugs. Briefly, this approach generates a complete recording of the fragment ion spectra of all 
the analytes in a sample within a determined m/z window and then acquired data from the 
chromatographic peak of each peptide is further used to determine the relative quantity of a 
certain protein. From a total of 1854 quantified proteins (GFP included), 489 proteins passed 
through the criteria mentioned in Experimental Procedure 4.9. The proteins were analyzed 
using SPSS (see Experimental Procedure 4.11), and in order to obtain more reliable results an 
outlier analysis was performed. Three of the replicates samples (CT4, HA1 and HA5) were 
eliminated, once the results for this samples were consistently considered outliers, which 
suggests that something could be wrong with each sample and not only with the proteins that 
were considered outliers. The rest of the proteins that were considered outliers were 
eliminated from the results and the p-values were determined, comparing the control data 
with each experimental group (haloperidol, clozapine and citalopram). Then, a fold increase 
analysis was performed comparing the same conditions (figure 5.8). The results were reported 
either if i) they were statistically significant when p < 0.05 and/or ii) proteins presented a ratio 
below than 0.66 or higher than 1.5 (figure 5.9).  
The graphic A in figure 5.8 shows that in the haloperidol condition half of the proteins 
were found up-regulated (ratio > 1, log10 scale > 0) and the other half was down regulated 
(ratio < 1, log10 scale < 0) relative to control.  
In the citalopram condition (graphic B) more than half of the proteins were up regulated 
(above zero) relative to the control. On the contrary, in the clozapine condition the majority 
of the proteins were down regulated (below zero) relative to the control.  
In haloperidol condition (figure 5.9, graphic A) 19 proteins were differentially regulated 
by this drug, and the majority (15 proteins) being up regulated relatively to the control 
condition, while 9 of them were down regulated to the control. The proteins with p < 0.05 
were 2, namely L-lactate dehydrogenase B chain, which was down regulated in relation with 
the control and UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa 
subunit that was up regulated relatively to the control. 
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Figure 5.8: Differential protein expression analysis induced by psychotropic medication. Fold-
increase of quantified proteins in a (A) Haloperidol, (B) Citalopram and (C) Clozapine. The relative quantitative 
A 
B 
C 
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proteins are presented in a log scale and were normalized for the control. The dashed line represents the fold-
increase and fold-decrease (0.66 and 1.5 in the log scale). 
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Figure 5.9: Differential protein expression analysis induced by psychotropic medication. Fold-
increase of quantified proteins in a (A) Haloperidol, (B) Citalopram and (C) Clozapine. The relative quantitative 
proteins are presented in a log scale and were normalized for the control. The criteria for the selection of this 
proteins were the following: p < 0.05 and/or ratio below 0.66 or above 1.5 (dashed lines). The proteins with the 
signal (*) were statistically significant with a p < 0.05.  
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In the citalopram condition (figure 5.9, graphic B) 23 proteins were considered altered 
by the drug, 21 of them were up regulated in relation to the control and 2 of them were down 
regulated. In this condition the Drebrin-like protein, Neurofilament heavy polypeptide, 
Kinesin-like protein KIF21A, Ubiquitin carboxyl-terminal hydrolase 14, Sodium/potassium-
transporting ATPase subunit alpha-1, Protein kinase C epsilon type and Calcium/calmodulin-
dependent protein kinase type II subunit alpha, were the 7 proteins with p < 0.05 and all of 
them were up regulated in relation with the control. 
A total number of 39 proteins were considered altered in the clozapine condition (figure 
5.9, graphic C), 9 of them were up regulated and 30 of them were down regulated in relation 
with the control condition. The proteins with a p < 0.05 were Neurofilament heavy 
polypeptide, Excitatory amino acid transporter 2, Sodium/potassium-transporting ATPase 
subunit beta-1, Kinesin-like protein KIF21A and Ubiquitin carboxyl-terminal hydrolase 14 and 
although the majority of the proteins in this condition were down regulated, these proteins 
were up regulated in relation to the control condition.  
Relatively to the proteins that were altered by the drugs, some of them are common 
regulated by the medications (table 5.2). 
 
Table 5.2: Differential protein expression commonly regulated between the psychotropic 
medications. ↑ - up regulated protein; ↓ - down regulated protein. 
 
Common Proteins  Haloperidol Citalopram   Clozapine
Calcineurin subunit beta type 1  ↑  ↑  ↓ 
Calcium/calmodulin‐dependent protein kinase type II subunit alpha  ↑  ↑  ↑ 
Phenylalanine‐‐tRNA ligase beta subunit  ↓  ↓  ↓ 
Protein kinase C epsilon type  ↑  ↑  ↑ 
Beta‐actin‐like protein 2  ↑  ↑    
Dihydrolipoyllysine‐residue acetyltransferase component of pyruvate dehydrogenase 
complex, mitochondrial  ↑  ↑    
Kinesin‐like protein KIF1A  ↑  ↑    
Phosphatidylethanolamine‐binding protein 1  ↑  ↑    
Proteasome subunit beta type‐3  ↑  ↑    
UDP‐N‐acetylglucosamine‐‐peptide N‐acetylglucosaminyltransferase 110 kDa subunit  ↑  ↑    
Haloacid dehalogenase‐like hydrolase domain‐containing protein 2  ↑     ↓ 
Long‐chain‐fatty‐acid‐‐CoA ligase ACSBG1  ↓     ↓ 
Serine/threonine‐protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform  ↓     ↓ 
Kinesin‐like protein KIF21A     ↑  ↑ 
Neurofilament heavy polypeptide     ↑  ↑ 
Phosphatidylinositol 5‐phosphate 4‐kinase type‐2 gamma     ↑  ↓ 
Sodium/potassium‐transporting ATPase subunit beta‐1     ↑  ↑ 
Ubiquitin carboxyl‐terminal hydrolase 14     ↑  ↑ 
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 The results above showed that clozapine (atypical antipsychotic) expressed more altered 
proteins than typical antipsychotic haloperidol, as well as, the majority of the proteins were 
down regulated by clozapine while with Haloperidol the majority of the altered proteins were 
up regulated. These results might explain the molecular mechanisms underlying the different 
effects of both drugs on the organism (described in the Introduction 1.2).  
 In order to determine which functional group the differentially regulated proteins 
belong an analysis using the software PANTHER and based in Biological Processes was 
performed (see Experimental Procedure 4.10) (figure 5.10). 
 
 
 
 
Figure 5.10: Pie charts illustrating the biological processes of the proteins differently regulated in 
the three drugs conditions.  Proteins selected with a fold increase of 1.5 and fold decrease of 0.66 and/or p 
< 0.05 were used for this analysis.   
 
 
 
 
 
 
 
apoptotic process    
 
 
biological adhesion    
 
 
biological regulation    
 
 
cellular component organization or biogenesis 
 
 
cellular process    
 
 
developmental process    
 
immune system process    
localization    
 
metabolic process    
 
multicellular organismal process  
 
reproduction    
response to stimulus    
Haloperidol Citalopram Clozapine 
62 | R E S U L T S  A N D  D I S C U S S I O N   
 
 
                                                            
 
 
Figure 5.11: Pie charts illustrating the biological processes of the proteins differently regulated in 
the three drugs conditions. Proteins selected with a fold increase of 1.5 and fold decrease of 0.66 and/or p < 
0.05 were used for this analysis.  The pie chart section of metabolic process in the previous figure (5.10) was 
selected to each condition.   
 
 
               
  
Figure 5.12: Pie charts illustrating the biological processes of the proteins differently regulated in 
the three drugs conditions. Proteins selected with a fold increase of 1.5 and fold decrease of 0.66 and/or p < 
0.05 were used for this analysis. A pie chart section of primary metabolic process in previous figure (5.11) was 
selected to each condition.   
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Figure 5.13: Pie charts illustrating the biological processes of the proteins differently regulated in 
the three drugs conditions. Proteins selected with a fold increase of 1.5 and fold decrease of 0.66 and/or p < 
0.05 were used for this analysis.  A pie chart section of protein metabolic process in previous figure (5.12) was 
selected to each condition.   
 
The results in the figure 5.10, show that the majority of the differentially regulated 
proteins were integrated into two functional processes, namely metabolic (grey part) and 
cellular process (blue part). In the cellular process the proteins were classified into two groups, 
protein phosphorylation and cell communication (data not shown). In metabolic process the 
majority of the proteins belong to the primary metabolic process (orange part) for the three 
drugs (figure 5.11), but in relation on the rest of the functional groups there are differences 
between the three drugs. In the haloperidol condition the proteins also belong to generation 
of precursor metabolites and energy, phosphate-containing compound metabolic process and 
coenzyme metabolic process. In the citalopram condition the functional groups are only two: 
the primary metabolic process, common for the three drugs, and the coenzyme metabolic 
process. For the clozapine conditions the proteins belong to the groups mentioned above and 
also to the biosynthetic process and nitrogen compound metabolic process.  
Also in primary metabolic process there are differences between the three drugs (figure 
5.12). The majority of the proteins belong to the protein metabolic process (blue part) for the 
three conditions. The proteins, although in less quantity, that belong to lipid metabolic process 
(orange part) are common for all the conditions, but proteins of carbohydrate metabolic 
process were regulated only by haloperidol and citalopram drugs, while proteins of 
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nucleobase-containing compound metabolic process and cellular amino acid metabolic process 
were regulated by citalopram and clozapine. Haloperidol is the only that regulated proteins 
that belong to the tricarboxylic acid cycle.  
Inside of protein metabolic process there are also differences between the drugs (figure 
5.13). The majority of the proteins belong to the cellular protein modification process and 
were regulated by the three drugs. Although in less quantity the proteins that belong to the 
proteolysis and translation were also regulated by the three drugs, and proteins belonging to 
protein complex assembly and protein folding only were regulated by clozapine.   
 Many studies have reported antipsychotic drugs may affect several metabolic pathways 
(Thomas et al., 2003), and this is the main path altered by the drugs in this study, but several 
other processes seems to be affected. Proteins belonging to the apoptotic pathways were 
altered in this study by the three drugs (figure 5.10), inducted expression of this proteins was 
already showed by haloperidol (Ahmed et al., 2012) and genome-wide analyses have implicated 
apoptotic pathways in the genetics of schizophrenia (Sequeira, Martin and Vawter, 2012;,Catts 
and Weickert, 2012). Proteins from immune system also were related here as altered by the 
drugs, and recent genetic association studies have provided evidence for the deregulation of 
the immune system, since immune abnormalities endure into adulthood and anti-inflammatory 
agents appear to be beneficial to the disease (Michel, Schmidt and Mirnics, 2012).  
Inside the metabolic processes affected by the drugs, the glucose and lipid metabolisms 
are the most referred in the literature (Thomas et al., 2003;, Lieberman and Stroup, 2005) and 
the results of this study present the lipid metabolism as an altered pathway by the three drugs. 
Although these pathways have not yet been reported as altered by drugs or in the disease 
cellular protein modifications, translation and proteolysis processes were altered by the drugs 
in this study and these may be of particular importance in the mechanisms of psychotic drugs 
action and in the pathophysiology of disorder. 
Proteins as Calcineurin subunit B type 1 and Calcium/calmodulin-dependent 
protein kinase type II subunit alpha, both differently regulated  by the three drugs,  as 
well as, Calretinin protein down regulated by clozapine, are involved in calcium pathways or 
dependent on it, which confirms the involvement of the drugs in calcium homeostasis. These 
findings are in line with the fact that several proteins related to calcium signaling have already 
been found regulated by antipsychotic medication (Kashem et al., 2009;, Thomas et al., 2003). 
Alterations of the intracellular calcium in schizophrenia has also been reported in the literature 
(Martins-de-Souza, 2011; Melkersson, 2010), which means that the proteins changes 
mentioned above due to the drugs could influence the outcome in SCZ disease.  
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Calcium/Calmodulin-dependent Kinase type II (CaMKII) is one of the most densely 
expressed proteins in the central nervous system. The intracellular signaling pathways that are 
controlled by CaMKII have been shown to be important for memory formation by controlling 
synaptic plasticity. The CaMKII holo-enzyme is essential for pre- and post-synaptic mechanisms 
at both excitatory and inhibitory synapses in hippocampal, amygdalar, cortical, and cerebellar 
neurons, which highlights the importance of this molecule for proper neuronal functioning 
(Gao et al., 2014). In this study the CaMKII subunit alpha was found up regulated by the 
treatment of the three drugs. Several studies reported this protein as down regulated in SCZ 
model animals,  according (Zhou et al., 2012) CaMKIIα was greatly down regulated after the 
MK-801 treatment both in the synaptosomal fraction and in the cerebral cortex. Another 
study proved that mice heterozygous for a null mutation of the alpha-isoform of 
calcium/calmodulin-dependent protein kinase II (alpha-CaMKII+/-) have profoundly 
dysregulated behaviours and impaired neuronal development in the dentate gyrus. The 
behavioral abnormalities include a severe working memory deficit and an exaggerated infradian 
rhythm, which are similar to symptoms seen in schizophrenia, bipolar mood disorder and 
other psychiatric disorders (Yamasaki et al., 2008). Therefore, the results present in this study 
suggest that the increase of CaMKIIα protein by all the drugs could be an important 
mechanism of action to antagonize the low levels of this protein in psychiatric disorders.  
According to (Walton et al., 2012) an emerging class of mouse models for SCZ and 
bipolar disorders (BPD) display similar cognitive impairments to those observed in human 
patients. The hippocampus of these mice possess a conserved pathophysiological alteration; 
the given term is the ‘immature dentate gyrus’ (iDG). The animals possessing an iDG are 
defined by increased expression of immature neuronal markers (including doublecortin and 
calretinin) and reduced levels of mature neuronal markers, most notably calbindin. With the 
objective to validate this class of mouse model the authors of this study confirmed that human 
SCZ and BPD patients displayed significantly elevated calretinin expression in the dentate 
gyrus and trending declines in calbindin expression (in BPD patients) when compared with 
control subjects, and patients suffering from major depression, meaning that calretinin 
overexpression in both SCZ and BPD patients was closely associated with a psychosis 
diagnosis and suicide risk (Walton et al., 2012). Thus, the down regulation of the calretinin 
protein by the Clozapine drug observed in this project proves to be significant, once this 
decrease could contribute to the outcomes of the SCZ disease. 
The proteins L-lactate dehydrogenase B chain and creatine kinase B-type down 
regulated by haloperidol and clozapine, respectively, also have been reported as altered in 
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more than one study of the human proteome of subjects with Schizophrenia (Dean, 2011; 
Deng et al., 2011). 
 In the case of excitatory amino acid transporter 2 (EAAT2) it was found up 
regulated by clozapine (figure 5.9), while (Schmitt et al., 2003) observed the opposite effect 
where clozapine significantly down regulated EAAT2 in hippocampus, temporal, cingulate and 
frontal cortex compared to the control. EAAT2 belongs to a family of Na+ dependent 
glutamate transporters that maintain a low synaptic concentration of glutamate by removing 
glutamate from the synaptic cleft into astroglia and neurons (Shan et al., 2014). It also 
contributes to energy metabolism in the brain, by transporting glutamate into astrocytes for 
conversion into glutamine (Spangaro et al., 2012). The glutamate hypothesis of schizophrenia 
is based on the observation that phencyclidine, a NMDAR antagonist leading to a glutamatergic 
hypofunction, gives rise to a schizophrenia-like psychosis (Schmitt et al., 2003). A glutamatergic 
deficit can be due to defective receptors, inadequate glutamate release or hyperactive 
glutamate transporters. Glutamate transporters control glutamatergic neurotransmission by 
removal of glutamate from the synaptic cleft. 
Different studies focused on EAAT2 alterations among subjects affected by 
schizophrenia, reporting a decreased expression in the parahippocampal region and in the 
dorsolateral prefrontal cortex (Spangaro et al., 2012). This protein, as well as, excitatory amino 
acid transporters 1 and 3, were found down regulated in the superior temporal gyrus, and in 
the hippocampus of patients with schizophrenia and the authors of the same study did not 
detect an effect of antipsychotic medication on expression of this protein in the temporal 
association cortex or hippocampus in rats treated with haloperidol for 9 months (Shan, 2014).  
Another study found evidence for less glycosylation of the EAAT1 and EAAT2 proteins in 
schizophrenia (Bauer et al., 2010). Therefore, the results in the present study suggest that the 
increased expression of EAAT2 in consequence of clozapine administration could be 
important, once it may be a compensatory mechanism of the decrease observed in the disease. 
An increase in this transporter could lead to the stabilization of the glutamate levels in the 
brain which could lead to the benefic effects of this drug observed in SCZ patients.  
 
 
  
CONCLUSION AND FUTURE PRESPECTIVES 
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6. CONCLUSION AND FUTURE PERSPECTIVES 
 
The main goal of this study was to identify the proteomic medication-associated changes 
of prefrontal cortex from mice treated with Haloperidol, Clozapine and Citalopram, as the 
molecular mechanisms responsible for the differences in the clinical profile of the drugs 
mentioned above remain unclear. 
A subproteome fractionation of the tissue was successfully  accomplished  and  the 
membrane protein fraction was separate from soluble protein fraction. The proteins NMDAR 
and  VDAC‐1  were  used  as membrane markers;  and  the  protein  DJ‐1  as  soluble marker, 
confirming  that were an enrichment of membrane and soluble proteins  in membrane and 
soluble fractions, respectively.    
In order to focus on the intracellular proteomic changes, in this project only the soluble 
proteins were analyzed. Firstly the identification of the proteins was performed by LC‐MS/MS 
in the four conditions (control and the three pharmacological treatments). The total number 
of  proteins  identified  was  similar  in  the  four  conditions  (around  1500),  although  the 
citalopram group present a  slightly higher number, and  the proteins  identified  in  the  four 
groups belonged all to the same cellular, molecular and biological processes. 
Then, a recently developed label free quantitative method (SWATH) was used to allow 
the quantification of an elevated number of proteins with a high confidence (489 proteins). 
After the outlier analysis, three of the replicates samples (CT4, HA1 and HA5) were 
eliminated, once several proteins appeared as outliers in these samples. 
Significant altered proteins were considered outside of the 1.5 fold factor (1/1.5 - 1×1.5 
i.e. below 0.66 and above 1.5) and/or with a p < 0.05. In the three drug conditions 14 proteins 
presented a p < 0.05 and 3 of them present a p < 0.01.  Clozapine presented a higher number 
of differentially regulated proteins according to these criteria (39 proteins), followed by 
citalopram (23 proteins), and then by haloperidol (19 proteins). This could explain the different 
effects observed by the drugs revealed different mechanisms of action.  
The Panther analysis revealed that the use of these drugs has a major effect in proteins 
involved in the metabolism, although other processes related with SZC were identified, 
namely: apoptotic, immune pathways and calcium homeostasis.  
Finally, the results in the present study suggest that the increased expression of the 
proteins CaMKIIα by all the drugs and the EAAT2 in consequence of clozapine 
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administration, as well as, the down regulation of the Calretinin by the use of clozapine could 
be important, once it may be a compensatory mechanism of the regulation in the disease. 
 In the future, the most interesting proteins must be validated in a targeted analysis for 
example, by western blot, as well as, quantify these proteins in post-mortem tissue of 
individuals with and without these therapies. Also, considering the availability of the other 
tissues, protein fractions (enrichment membrane proteins) and a metabolites fraction (not 
mentioned), the analysis and combination of all results can contribute to elucidate the overall 
changes induced by these drugs.   
Altogether, these findings can give new insights of future strategies for the treatment 
and prevention of the progression of SCZ once it shows new directions for recognizing 
disease-related changes.  
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8. SUPPLEMENTARY DATA 
 
8.1. OPTIMIZATION OF THE SUBPROTEOME FRACTIONATION 
PROCEDURE 
The goal in the subproteome fractionation procedure (see Experimental Procedure 4.2) 
was separate the maximun of membrane proteins from the other proteins simplifing the 
samples. A second ultracentrifugation step was performed in order to understand if the 
eficiency of the separation was increased.  
In this procedure cortexes from rats that were not injected with any kind of drugs were 
used, kidly provided by Center for Neuroscience and Cell Biology of Coimbra. The 
Supplementary figure 8.1 shows a scheme of the subproteome fractionation procedure with a 
second ultracentrifugation step (w).  
 
Supplementary Figure 8.1: Scheme of the membrane protein enrichment procedure with the 
second ultracentrifugation step. E3- extract from the cortex 3, obtained before subproteome fractionation, 
two other aliquots (3 and 3’) were subjected to sonication, centrifugation to remove tissue debris, and the 
supernatant subjected to ultracentrifugation; M3- membrane protein fraction from cortex 3, obtained after the 
first ultracentrifugation step; M3w- membrane protein fraction from cortex 3, obtained after the second 
ultracentrifugation step;   S3-  soluble protein fraction from cortex 3, obtained after the first ultracentrifugation 
step; S3’- soluble protein fraction from cortex 2, obtained after the first ultracentrifugation step; S3w- soluble 
protein fraction from cortex 3, obtained after the second ultracentrifugation step. The same code applies to 
cortex 6 and 9. 
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Briefly, extract samples were obtained before the first ultracentrifugation step, these 
contained the membrane and soluble proteins. After the first hour of ultracentrifugation and 
the removal of supernatants (soluble fraction), it was added 2 mL of Tris 0.05 M to the pellets 
M3’, M6’ and M9’ and a second ultracentrifugation at 144,000×g for 1 hour at 4ºC was 
performed. The supernatant of these samples were taken again and 1 mL of TEAB 0.5 M was 
added to all the pellets. The pellets were then dissolved using the ultrasonicator with the 3 
mm probe for 30 seconds at 40% to 50% amplitude with 1 second cycles, this step was 
repeated until total dissolution. Acetone was used for protein precipitation in all samples.  
After the subproteome fractionation procedure protein concentration of each samples 
was obtained by 2-D Quant Kit (see Experimental Procedure 4.4). In the Supplementary table 
8.1 the total amount of each sample and the percentage of recovery relative to each extract 
was calculated.  
The amount of protein content in the extract samples was higher than in the other 
fractions, as expected, once the extract samples contain membrane and soluble proteins. The 
amount of protein content  in the membrane fraction were superior than the soluble samples. 
Although the amount of membrane proteins in a cell is less than the other proteins, in this 
procedure cytoskeletal proteins also remain in the membrane fraction, increasing its protein 
content. 
It was not possible to quantify the soluble fractions obtained after the second 
ultracentrifugation step (S3w, S6w and S9w) as the 2-D Quant Kit has a small range of 
absorvance values and the absorvance of these samples were outside the calibration curve 
meaning  that the amount of protein in these fractions was very low.  
The amount of protein in soluble and membrane fractions obtained after the first 
ultracentrifugation step (S3, S6, S9, M3, M6 and M9) was higher than the amount of protein in 
soluble and membrane fractions obtained after the second ultracentrifugation step (S3w, S6w, 
S9w, M3w, M6w and M9w), consequently with a second ultracentrifugation step the amount 
of protein that is separated is lower than the amount in the first step of ultracentrifugation.  
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 The percentage of recovery is the sum of the total amount of the samples of each cortex 
divided by total amount of the respective extract sample. In the cortex 3 and 9 the percentage 
of recovery was 84.21 and 83.68%, respectively, as expected, once is very difficult to achieve 
100% of the protein recovery, since there are losses of protein is each step throughout the 
procedure. However, in the cortex 6 the percentage of recovery was 68.49%, slightly lower 
than the others cortexes, in that case the protein amount in the extract sample was similar 
with the other extracts samples but the protein amount in the membrane and soluble samples 
were lower, therefore it is probable that in these samples there was a greater loss of protein 
content.  
 In order to evaluate the subproteome fractionation procedure a SDS-PAGE followed by 
Coomassie staining was performed. The samples that were used to this procedure suffered 
the same subproteome fractionation process described in the Supplementary figure 8.1, the 
only difference is that the samples came from other rat cortexes specifically cortex 2, 5 and 
8. The soluble samples (S5w and S8w) obtained after the second ultracentrifugation step were 
lost during the procedure. Briefly, samples (20 µg of total protein) were denatured with the 
addition of Laemmli Sample Buffer 6× to a 1× final concentration and boiled at 95ºC for 5 
minutes. 
 Afterwards the samples were electrophoretically separated in a 1.25 mm gel (12.5%) of 
SDS-polyacrylamide gel using a Mini-PROTEAN Tetra Electrophoresis System. To evaluate the 
SDS-PAGE profile the gel was stained with Colloidal Coomassie Blue (see Experimental 
Procedure 4.6). After successive washes with distilled water the gel was scanned to be 
visualized (Supplementary figure 8.2). 
 
 
 
 
 
 
 
 
 
Supplementary Figure 8.2: Analysis of protein profile after membrane enrichment procedure by 
SDS-PAGE. SDS-PAGE followed by Coomassie staining. MW- molecular weight marker (BioRad). See 
supplementary figure 8.1 caption for further details. 
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 In the upper part of the gel (Supplementary figure 8.2), it is possible to visualize that the 
profile of the membrane samples was very similar between them, and the same occurred with 
the soluble samples. As expected, the profile of the membrane, soluble and extract samples 
was different, an example is the intense band in the 50 kDa that only appears in the membrane 
fractions. It was possible to observe on top of the gel a deeper color in the membrane fractions 
than in the extract and soluble fractions, which means that there were more proteins with a 
high molecular weight in this samples (which are usually associated to membrane proteins). 
On the contrary a deeper color was observed in the bottom of the gel in the soluble fractions, 
so there were more proteins with a low molecular weight in these samples (possibility soluble 
proteins). The intense band (50 kDa) in the membrane fractions, but less intense in the extract 
sample, means that there was an enrichment of proteins in these samples. The sample is 
observed with the intense bands between (37 and 50 kDa) in the soluble fractions that were 
also less intense in the extract fraction, and in the membrane samples did not exist. It is 
possible to conclude that there was an enrichment of the proteins in the fractions comparing 
with the extract sample that were not subjected to a subproteome fractionation.  
8.1.1. Evaluation of the subproteome fractionation procedure 
 
In order to evaluate the subproteome fractionation procedure a comparison of the 
number of shared or unique proteins from samples that were identified by mass spectrometry 
was performed using a Venn diagram Supplementary figure 8.3, (Experimental procedure 4.10). 
The procedure for gel digestion was described in Experimental Procedure 4.6. The IDA 
conditions for gel digestion were similar to Experimental Procedure 4.8 except the parameters 
for search: Uniprot_SwissProt database for rat (updated in February 2014); trypsin digestion; 
acrylamide for gel digestion, as cysteine alkylating reagent. 
The comparison between all gel digestion samples revealed that 313 proteins were 
shared by all the samples. The number of unique proteins in the membrane and soluble samples 
obtained after a first ultracentrifugation (M3 and S3) were higher relative to the rest of the 
samples. 
As expected, the number of unique proteins in the extract sample was only 34, much 
lower than the unique proteins in the M3 and S3 samples, meaning that there is an enrichment 
of proteins in this two samples after the subproteome procedure. A very low number of 
unique proteins was identified in the samples that were obtained after a second 
ultracentrifugation step (M3w and S3w). 
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Supplementary Figure 8.3: Venn diagram illustrating the number of shared or unique proteins 
from gel digestion that were identified by Mass spectrometry for all samples. There are 313 common 
proteins between all samples and the combined protein number is 1540. 
 
These results, as well as the time required to perform a second ultracentrifugation step, 
are sufficient to consider that this step does not make the procedure more efficient and 
consequently was not applied to the final samples. 
 In order to confirm if the membrane enrichment mentioned above was accomplish, a 
GO enrichment analysis of the identified proteins in gel digestion samples (E3, M3 and S3), 
respectively was performed (Supplementary figure 8.4). In this analyze two ranked lists were 
used i) the proteins from each sample against ii) all proteins that were identified in this 
procedure. 
 The GO enrichment analysis in the extract sample (Supplementary figure 8.4, A) 
indicates that the proteins statistically significant (p < 10-9) in this sample belong to the 
extracellular region of the cell (red boxes) also cytoplasm and organelle protein present some 
statistical significance (p < 10-5 to 10-9) (orange and yellow boxes) in these samples. In the 
membrane fraction (B) the analysis indicates that the proteins statistically significant (red boxes 
in C) belong to the plasma membrane in the cell, while in the soluble fraction (D) the protein 
belongs to the cytoplasm, cytosol, nucleus and extracellular region of the cell (red boxes), as 
expected.  
Total numer: 1540 
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A                                                              E3 
 
 
B                                                             M3 
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C                                                            M3 
 
D                                                             S3  
 
 
 
 
Supplementary Figure 8.4: Evaluation of the membrane enrichment procedure. Gene Ontology 
(GO) Enrichment of the identified proteins of the gel digested samples.  A- proteins identified in the 
extract sample from cortex 3 (E3) against all the proteins that were identified; B- proteins identified in the 
membrane sample from cortex 3 (M3) against all the proteins that were identified C- zoom view of the red boxes 
of the M3 sample; D- proteins identified in the soluble sample from cortex 3 (S3) against all the proteins that 
were identified. 
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  This results indicated that in the extract sample there was not an enrichment, as 
expected, once this sample did not suffered a subproteome fractionation, but in the membrane 
fraction an enrichment in membrane proteins was observed, as well as, an enrichment in other 
proteins mostly from cytoplasm was observed in the soluble fraction, as expected.  
 These results serve as proof-of-concept for membrane protein enrichment procedure, 
in the membrane fraction, and its depletion from the soluble fraction. 
 
8.2. SOLVENTS FOR THE PROTEIN PRECIPITATION 
 
In order to determine which solvent would be the best to precipitate the soluble and 
membrane proteins in the fractions, three different solvents were used namely: acetone (6 
parts), methanol (4 parts) and methanol/chloroform (1.5 parts of MeOH and 3 parts of 
CHCl3). 
The samples used to perform this analysis were processed using the same protocol as 
previous samples (see Supplementary Subchapter 8.1), but in the present procedure the three 
organic solvents were used to precipitate the proteins. A liquid digestion were performed to 
the samples (once this procedure is shorter) and the proteins were identified by mass 
spectrometry. In liquid digestion, samples were resuspended in a TEAB 0.5 M solution to a 
final volume of 45 µL and denatured using a sonicator with cuphorn during 1 min at 20% 
amplitude with 1 second cycles, after the addition of 4 µL Tris(2-carboxyethyl)phosphine 
(TCEP) 50 mM, a reducing agent. To promote the cysteine alkylation was added 2 µL of S-
methyl methanethiosulfonate (MMTS) 200 mM were added and the samples were incubated 
at room temperature during 10 minutes. The reaction was quenched by the addition of TEAB 
at 0.5 M and Trypsin, at 0.5 µg/µL in TEAB 0.5 M, was added to a final ratio of 1:20 (w:w). The 
digestion was held at 37ºC during 16 hours. After this period 2 µL of formic acid 100% were 
added to stop the trypsin’s activity and the samples containing the peptides were concentrated 
on the Concentrator Plus at 60ºC. The IDA conditions for liquid digestion were similar to 
Experimental Procedure 4.8 except the parameters for search: Uniprot_SwissProt database 
for rat (updated in February 2014); trypsin digestion; MMTS as cysteine alkylating reagent.  
The total number of identified proteins in each sample is present in the Supplementary 
figure 8.5.  
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Supplementary Figure 8.5: Total number of proteins identified by Mass Spectrometry. Extracts- 
Extracts from cortex A, B and C; Membrane (Acetone)/ (Methanol)/ (Methanol/Chloroform) - Membrane protein 
fractions from cortex A, B and C precipitated with acetone, methanol and methanol/chloroform, respectively. 
Soluble (Acetone)/ (Methanol)/ (Methanol/Chloroform) - soluble protein fractions from cortex A, B and C 
precipitated with acetone, methanol and methanol/chloroform. The results represent mean values ± SEM. 
 
 As it can be seen, the number of proteins identified was approximately the same in each 
sample. In the membrane fraction where acetone was used the number of proteins identified 
was less than the other membrane fractions, and the membrane fractions where methanol 
were used also had less proteins identified than in the case of membrane fractions where it 
was used methanol/chloroform. The percentage of membrane proteins that were identified in 
the membrane fractions was similar (approximately 59%) for the three organic solvents. 
Although the results for samples that were processed using methanol/chloroform were slightly 
better, the procedure with this solvent was more laborious and prone more variability. The 
samples presented a phase separation disc (membrane fraction) instead of a rigid pellet, which 
difficult the removal of the soluble fraction and the elimination of the solvent, therefore 
methanol is the solvent suggested to be used in the processing of membrane fractions. 
In the soluble samples the difference is even smaller, the number of the identified protein 
and the percentage of the membrane proteins is very similar for the three organic solvents. 
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Consequently, for the soluble fraction the solvent acetone was chosen to be used in the final 
samples, once it presents a smaller standard deviation. 
 
8.3. OPTIMIZATION OF THE WESTERN BLOTS FOR THE EVALUATION 
OF THE SUBPROTEOME FRACTIONATION PROCEDURE 
8.3.1. PSD-95 and GAPDH as protein markers 
 
PSD-95 is a synaptic scaffolding protein with multiple protein–protein interaction 
domains that is enriched in the postsynaptic density, an electron-dense specialization of 
postsynaptic membrane that contains macro-molecular protein complexes. PSD-95 has 
diverse synaptic functions. One such function is to interact with membrane proteins and 
regulate their synaptic localization. PSD-95 seems to stabilize interacting membrane proteins 
at synapses by suppressing their lateral diffusion or internalization (Han, K. and Kim, 2008).  
GAPDH is an enzyme with metabolic function, in particular in glycolysis process, thus 
serves to break down glucose for energy and carbon molecules (Krishnan et al., 2010). This 
protein is commonly used as a cytoplasmic marker in proof-of-concept of subproteome 
fractionations procedures (Murray, Barrett and Eyk, 2009), cell fractionation kit (Abcam®) and 
nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific).  
Therefore, PSD-95 and GAPDH were tested as membrane and soluble markers, 
respectively, for the evaluation of the subproteome fractionation procedure. 
The sample “N” was used for normalization, these contained 10 µg of protein from all 
samples that were used in SDS-PAGE procedure. The samples used were the same used in 
the procedure above (Supplementary Data 8.1).  
The samples (30 µg of protein) were denatured with the addition of Laemmli Sample 
Buffer 6× [0.35M Tris-HCl, pH 6.8 with 0.4% SDS (v/v), 30% glycerol (v/v), 10% SDS (w/v), 
9.3% DTT (w/v) and 0.01% bromophenol blue (w/v)]  to a 1× final concentration and boiled 
at 95ºC for 5 minutes. Samples were electrophoretically separated on a 10% SDS-
polyacrylamide gel using a Mini-PROTEAN Tetra Electrophoresis System. After the 
transference to the membrane (see Experimental Procedure 5.1.2) these were incubated with 
the antibodies goat Anti-PSD95 C-20 (1:500) [Santa Cruz Biotechnology, Inc. (sc-8575)], 
mouse Anti-GAPDH G-9 (1:500) [Santa Cruz Biotechnology, Inc. (sc-365062)] and their 
respective secondary antibodies. The molecular weight of PSD-95 and GAPDH antibodies 
were 95 kDa and 37 kDa, respectively. The volume applied in the soluble samples S3w, S6w 
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and S9w were the maximum possible, once it was not possible to determine the protein 
concentration on these samples (Supplementary Data 8.1, table 8.1).  
As expected, intense bands could be observed in all membrane and extract samples, as 
well as, in the N sample, for PDD-95 detection (figure 8.6), while bands with less intensity 
were detected in soluble samples. The results for GAPDH were not expected, since bands 
were observed for all the samples, in that case would be expected bands only in the soluble, 
extract and N samples, whereas the GAPDH is used here as a soluble marker.  
 
  
 
 
 
Supplementary Figure 8.6: Evaluation of the subproteome fractions procedure. Imunodetection 
of PSD95 as a membrane marker and GAPDH as a soluble marker. Extracts- extracts from the cortex 
3, 6 and 9; Membrane- membrane protein fractions from cortex 3, 6 and 9, obtained after the first 
ultracentrifugation step; Membrane w- membrane protein fractions from cortex 3, 6 and 9, obtained after the 
second ultracentrifugation step;   Soluble- soluble protein fractions from cortex 3, 6 and 9, obtained after the 
first ultracentrifugation step; Soluble w- soluble protein fractions from cortex 3, 6 and 9, obtained after the 
second ultracentrifugation step. The results represent mean values ± SEM. 
The PSD-95 detection (grey bars) was higher for membrane samples (both, membrane 
and membrane w) than soluble samples (soluble and soluble w). In the extract samples the 
detection of PSD-95 was higher than the soluble samples but less comparing with the 
membrane samples, as expected. These results indicate that the PSD-95 could be found in 
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higher quantity in the membrane samples, as expected, but their higher standard deviation 
indicates that the data were spread over a range of values, lowering the confidence in these 
data. These results combined with the fact that PDS-95 protein interacts with membrane 
proteins but is not a real membrane protein decreases the confidence on this protein as a 
membrane marker.  
Although the detection of GAPDH was higher in the soluble samples (white bars), the 
detection of GAPDH in all samples, mainly in membrane samples indicated that this protein 
was not a good soluble marker for the evaluation of this procedure. In the literature GAPDH 
is mentioned several times as a cytoplasmic protein that innerves in metabolic processes but 
some studies showed that GAPDH could be found as a binding protein on the plasma 
membrane (Krishnan et al., 2010;, Laschet et al., 2004), which could justify the results obtained 
in this study. Antibodies for the detection of EGFR (epidermal growth factor receptor) and 
Shank 3 (SH3 and multiple ankyrin repeat domains 3) were tested (membrane and soluble 
markers, respectively) but the results were not in accordance to their use as fraction markers 
(data not shown).  
 
8.3.2. NMDA as a membrane marker  
 
The NMDA protein was used as a membrane marker to evaluate the subproteome 
fractionation procedure, but the results of western blot showed that the bands were in the 
area of the membrane correspondent to the stacking gel, it means that this protein could not 
enter in the running gel to be separated and the analysis was not possible (data not shown). 
These results indicate that the NMDA protein had not been correctly denatured, probably 
due to its complex structure, as it was previously reported (Results and Discussion 5.2). 
The denatured conditions applied to the samples before, were used to denatured the 
majority of the proteins in the lab and until this moment with excellent results, but in that case 
using  Laemmli Sample Buffer 6× [0.35M Tris-HCl, pH 6.8 with 0.4% SDS (v/v), 30% glycerol 
(v/v), 10% SDS (w/v), 9.3% DTT (w/v) and 0.01% bromophenol blue (w/v)] to a 1× final 
concentration and at 95ºC during 5 minutes did not permit a correct denaturation of the 
NMDA receptor in the samples, consequently there was the need to optimize this procedure. 
Denaturation is a process in which the protein lose the quaternary, tertiary and 
secondary structure which is present in their native state. For detection and analysis of the 
protein in a western blot procedure, firstly the proteins are denatured to be separated by gel 
electrophoresis. The application of the external stress or compounds as acid or base, 
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concentrated inorganic salt, organic solvent, radiation or heat leads to denaturation of 
proteins. Denatured proteins can exhibit a wide range of characteristics, from loss of solubility 
to communal aggregation. Therefore, the temperature condition of 95ºC during 5 minutes 
could cause the denaturation of the NMDA protein in the samples but due its complex 
structure the subunits were aggregated, which justify the bands in the staking gel region.  
To try to overcome this, a 60ºC temperature during 10 minutes was tested, such that 
the denaturation occurs slowly and to avoid the aggregation of the NMDA protein in the 
samples. Therefore, extract from membrane and soluble fractions (30 µg of protein) were 
used (Supplementary Subchapter 8.1). The 1× Laemmli Sample Buffer was used to each sample 
and the temperatures of 60ºC during 10 minutes or 95ºC for 5 minutes were applied to 
different samples. The electrophoretic separation was performed on a 10% SDS-
polyacrylamide gel using a Mini-PROTEAN Tetra Electrophoresis System. The antibodies used 
for NMDAR detection were described in Experimental Procedure 4.5.2.  
As it can be seen in figure 8.7 the detection of the NMDAR was observed only for the 
extract and membrane samples, for both temperatures conditions, as expected, but the bands 
in these samples were not clear. A smear can be seen in the stacking gel, which was not 
supposed, and bands in the molecular weight (115 kDa) correspondent of NMDA protein. 
These results indicate that the temperature decrease alone is not sufficient to denature 
properly the NMDA protein in these samples.  
 
 
 
  
  
 
Supplementary Figure 8.7: Immunodetection of the NMDAR as a membrane marker. E9- extract 
from the cortex 9, obtained before subproteome fractionation/membrane enrichment procedure, M9- 
membrane protein fraction from cortex 9, obtained after the first ultracentrifugation step; M9w- membrane 
protein fraction from cortex 9, obtained after the second ultracentrifugation step; S9- soluble protein fraction 
from cortex 9, obtained after the first ultracentrifugation step; S9w- soluble protein fraction from cortex 9, 
obtained after the second ultracentrifugation step. The 1 samples were denatured at 60ºC during 10min and the 
2 samples were denatured at 95°C during 5 min.  
Therefore, 37ºC of temperature during 30 minutes also were tested and the reagents 
concentration on the Laemmli buffer were changed. This time, only the membrane samples 
S92 M9w2 M92 E92 S9w1S91M9w1 M91 
NMDA → 
95°C     5 min 60°C   10 min   
E91 
Stacking Gel 
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were used, 30 µg of protein of M9 sample denatured with different conditions, as could be 
seen in Supplementary figure 8.8. The sample M91 was denatured at 37ºC during 30 minutes 
with SDS concentration increased to 12% and 4 M of NaCl added in the buffer 6×, in the M92 
sample the conditions were the same except this time NaCl was not added, in M93 and M94 
samples the temperature used was 60ºC during 10 minutes, with SDS increase to 12% and 
NaCl addition in the M93 and without the addition of NaCl in the M94, lastly in the M95 and 
M96 samples, urea 6 M were added in the buffer 6× and 60ºC during 10 minutes of temperature 
was tested for the M95 sample. In this procedure also the percentage of acrylamide in the gel 
were lower (7.5%) to help the NMDA protein to enter and to run through the gel.  
In the figure 8.8, the bands for 115 kDa could be observed for all samples in the 
different denaturation conditions. The bands in the stacking gel region that were observed in 
previous results were not observed here. And the bands in the samples there were denatured 
with the increase of the SDS concentration and the addition of the NaCl present a better 
intensity for both temperatures than the bands of the samples that were denatured only with 
a SDS concentration increase.  
SDS is an anionic detergent that denatures secondary and non–disulfide–linked tertiary 
structures, and additionally applies a negative charge to each protein in proportion to its mass, 
the increase of its concentration was essential to obtain a better denaturation of the NMDA 
protein. Proteins are biomolecules which occur in physiological environment with a delicate 
balance of salt concentrations. Too high or too low salt conditions can lead to precipitation 
of a protein, suggesting its denaturation, so NaCl addition was also essential to help the 
denaturation of the NMDAR in the samples. Urea is used in high concentrations (> 6 M) to 
denature proteins. It is a chaotropic agent that destroy is the tertiary and secondary structure 
of proteins by influencing hydrophobic effects hydrogen bonds and others. Nonetheless, in 
this procedure the samples that were denatured with urea did not present bands as intense 
as the bands observed in the rest of the conditions.   
As in the M93 sample the smearing of the signal in the lane was lower than the M91 
samples and with 60ºC it is possible save to time in the procedure, the denaturation conditions 
that were applied on the M93 samples showed better results for the NMDAR detection. 
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Supplementary Figure 8.8: Immunodetection of the NMDAR as a membrane marker. Mw- 
molecular weight marker; M91- Membrane protein fraction, denatured at 37ºC for 30 min with NaCl and SDS; 
M92- Membrane protein fraction, denatured at 37ºC for 30 min with SDS; M93- Membrane protein fraction, 
denatured at 60ºC for 10 min with SDS and NaCl; M94- Membrane protein fraction, denatured at 60ºC for 30 
min with SDS; M95- Membrane protein fraction, denatured at 60ºC for 10 min with urea; M9- Membrane protein 
fraction, denatured with urea.  
 The next step was to test other samples (extract, membrane and soluble) with the 
denaturation conditions previously chosen, so samples (30 µg of protein) that were process 
as the samples in Supplementary Subchapter 8.1 were used. The samples “N” was used as 
normalization of the samples between membranes and GFP protein was added to each sample 
to the normalization of the samples between each well, to account for pipetting errors. The 
denature conditions applied were the following: Laemmli Sample Buffer 6× [0.35M Tris-HCl, 
pH 6.8 with 0.4% SDS (v/v), 30% glycerol (v/v), 12% SDS (w/v), 9.3% DTT (w/v), 0.01% 
bromophenol blue (w/v) and 1.2 M NaCl]  to a 1× final concentration, 60ºC of temperature 
during 10 min (Supplementary figure 8.9).  
 Despite the presence of a labeling signal with the bands, intense bands were observed 
only in the extract, N and membrane samples, while in the soluble fractions very weak bands 
were observed, as expected. However, for GFP detection several nonspecific bands were 
observed, meaning that this new denaturation conditions was not indicated for the GFP 
protein.  
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Supplementary Figure 8.9: Immunodetection of the NMDA as a membrane marker with GFP 
protein as a standard normalization.  For more details see Supplementary figure 8.2. 
 
 Thus, the samples (30 µg of protein) were denatured with the denaturation condition 
described above and GFP protein was denatured separately with Laemmli Sample Buffer 6× 
[0.35M Tris-HCl, pH 6.8 with 0.4% SDS (v/v), 30% glycerol (v/v), 10% SDS (w/v), 9.3% DTT 
(w/v) and 0.01% bromophenol blue (w/v)]  to a 1× final concentration and boiled at 95ºC for 
5 minutes. After this, 0.84 ng of GFP protein was added to each sample and the SDS-PAGE 
procedure was performed in a 7.5% acrylamide gel. The western blot detection was performed 
as described in Experimental Procedure 4.5.2 for NMDA detection. Firstly, the analysis of the 
bands and the lanes with local background subtraction method were performed, as well as, 
the bands with global background, using Quantity One software (Supplementary figure 8.10).  
 Once the smearing of the signal in the lane continued to exist, a dot blot was performed 
using the same samples (Supplementary figure 8.10, E) and compared with different band data 
processing (Supplementary figure 8.10). Briefly, samples (2 µg of protein) were added directly 
to a pre-activated, with methanol, PVDF membranes. The membranes were blocked for 1 
hour at room temperature with 5% (w/v) skimmed milk powder dissolved in PBS with 0.1% 
(v/v) Tween-20. Then the membranes were incubated with primary goat antibodies against 
Anti-NMDAR C-20 (1:500) in 5% (w/v) skimmed milk powder dissolved in PBS-T, overnight 
at 4ºC followed by 1 hour at RT. The antibodies incubation and detection was performed with 
the same conditions as the western blot procedure mentioned in Experimental Procedure 
4.5.2. 
M2w Mw E2 M2 S2 S2’ S2w N E5 M5 
←NMDA  100- 
25- ←GFP 
37 - 
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Supplementary Figure 8.10: Imunodetection and 
imuno-dot blot of NMDAR as a membrane marker.  
A- imunodetection of NMDAR as a membrane marker; B-
analysis of the bands with local background subtraction 
method; C-  analysis of the lanes with local background 
subtraction method; D- analysis of the bands with global 
background subtraction method; E- imuno-dot blot of 
NMDAR as a membrane marker F- dot blot analysis with 
local background subtraction method. The results of the 
graphics represent mean values ± SEM. 
NMDA → 
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As expected, intense bands are observed for the extract, membrane and N samples, 
while less intense bands could be seen in the soluble samples, also, only one band is observed 
for each sample in GFP detection (Supplementary figure 8.10, A). The graphic B and C 
represent bands and lane analysis, respectively, with a local background subtraction method 
(i.e., the final density in the selected area (bands or lanes) were obtained by subtraction of the 
intensity in this selected area by the intensity in the surrounding region) while in the 
Supplementary figure 8.10 D the bands were analyzed with global background subtraction 
method (i.e., a clean and small region of the membrane background was selected and used to 
the comparison of the bands intensity). The bands were analyzed with global background 
because the smearing of the signal in the lanes could influence the results of the analysis with 
local background, thus the selection of a clean region of the membrane could be better for 
the results. Besides the analysis of the bands, it was also performed the analysis of the lanes 
because of the same reasons mentioned above, the labeling of the signal in lanes could influence 
the analysis of the bands. 
 As can be seen in the three analysis the NMDAR detection (Supplementary figure 8.10 
A-D) were higher in membrane and extract samples than the soluble fractions and the intensity 
was higher in membrane samples comparing with the extracts samples, as expected. The 
profile of the three analysis was similar, except in the analysis of the lanes (Supplementary 
figure 8.10 C), where the density of the soluble fractions that were obtained after the second 
ultracentrifugation step (soluble wash) was 0 (Supplementary table 8.2), and therefore it did 
not have any statistical difference between the soluble fractions and the other samples. This 
results indicated that the smearing did not influence the results, and it won’t be needed to 
perform an analysis with a global background. 
 The dot blot procedure does not require a separation in a gel and therefore to the 
NMDAR complications referred above did not exist. Intense dots were observed in the 
membrane samples (Supplementary figure 8.10, E) comparing with the other samples, and the 
intensity of the NMDAR was higher in the extracts and membrane samples (black, orange and 
grey bars) comparing with soluble samples (white and blue bars) (Supplementary figure 8.10, 
F).  
 In the Supplementary table 8.2 the results for the extracts samples for the 4 analysis 
(0.84, 0.96, 0.84 and 0.94), as well as, the average for the membrane samples (0.96, 1.05, 1.18 
and 1.16) were similar between the samples. In the membrane wash samples the average for 
the lanes and bands with global background analysis was superior (1.81 and 1.66, respectively) 
than the bands and dot blot analysis (1.30 and 1.22, respectively). The average of the soluble 
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samples in the western blot analysis were similar for soluble samples (0.04, 0.01 and 0.05) and 
0.02 for soluble wash samples, while the average for the dot blot analysis was superior (0.64 
for soluble and 0.07 for soluble wash samples).  
 However the standards deviations and the percentage of coefficient of variation were 
much lower for all samples in the dot blot analysis comparing with the other three analysis. 
The results indicate that although the dot blot analysis present best standard deviations 
and percentage of CV thereby making them more reliable results, a higher detection of 
NMDAR in soluble samples comparing with the other analysis could lead to the conclusion 
that the separation of membrane and soluble samples in subproteome fractionation procedure 
were not efficient, which was not in line with the results by western blots and the mass-
spectrometry analysis (Supplementary Data 8.1.1). This increase in NMDA detection of soluble 
samples for dot blot analysis may be due to the fact that a high protein amount (2 µg of protein) 
were used which could lead to a signal saturation in the membrane samples.  
 
Supplementary table 8.2: Imunodetection and imuno-dot blot of NMDAR as a membrane marker. 
The average, standard deviation and the percentage of coefficient of variation were calculated using GraphPad 
software for the samples in different analysis (lanes and bands analysis with local background subtraction method, 
bands analysis with global background subtraction method and imuno-dot blot analysis).   
 
Samples   Mean  SD  %CV    
Extracts  0.84  0.36  42.82 
Western Blot 
(Bands) 
Membrane  0.96  0.32  33.40 
Membrane Wash   1.30  0.93  71.86 
Soluble   0.04  0.02  59.21 
Soluble Wash  0.02  0.03  125.32 
Extracts  0.96  0.49  51.31 
Western Blot 
(Lanes) 
Membrane  1.05  0.20  18.65 
Membrane Wash   1.81  1.48  81.57 
Soluble   0.01  0.02  150.07 
Soluble Wash  0.00  0.00  0.00 
Extracts  0.84  0.30  35.68 
Western Blot 
(Bands with 
Global 
Background) 
Membrane   1.18  0.43  36.06 
Membrane Wash   1.66  1.25  75.21 
Soluble  0.05  0.02  48.08 
Soluble Wash  0.02  0.03  173.21 
Extracts  0.94  0.26  27.97 
Dot Blot 
Membrane  1.16  0.24  20.39 
Membrane Wash   1.22  0.10  7.85 
Soluble   0.64  0.25  39.45 
Soluble Wash  0.07  0.02  23.52 
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8.4. COMPARISON OF LIQUID AND IN-GEL DIGESTIONS  
 
To cleave the proteins in peptides, liquid and gel digestions were performed, in order 
to evaluate with which one more proteins would be identified by mass spectrometry. The 
samples (Supplementary subchapter 8.1) (30 µg of protein) were used for both digestions, 
except in the S3w, S6w and S9w samples, once a protein quantification was not possible, that 
was used the maximum volume to make sure that the amount of protein was sufficient. The 
procedure for gel digestion was described before in Supplementary Subchapter 8.1.1 and for 
liquid digestion in Supplementary Subchapter 8.1.2.  
The Supplementary figure 8.11 represents the total amount of proteins identified by 
mass spectrometry for liquid and gel digestions, as well as, the percentage of membrane 
proteins in each sample.  
 
Supplementary Figure 8.11: Total number of proteins identified by Mass Spectrometry. Samples 
were digested either using the gel digestion (GD) or the liquid digestion (LD) protocol. E3- extract from cortex 
3, obtained before the subproteome fractionation; M3- membrane fraction from cortex 3, obtained after the first 
ultracentrifugation step; S3- soluble fraction from cortex 3, obtained after the first ultracentrifugation step; M3w- 
membrane fraction from cortex 3, obtained after the second ultracentrifugation step; S3w- soluble fraction from 
cortex 3, obtained after the second ultracentrifugation step. 
 The results showed that the number of membrane proteins (white part of the bars) that 
were identified in the extract samples, for both liquid and gel digestions, were approximately 
50%, as expected, once the extract samples contained membrane and soluble proteins, before 
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the subproteome fractionation. The membrane proteins in the membrane samples (M3 and 
M3w), for both digestions, were superior of the soluble proteins (grey part of the bars), 
approximately 63% and 59% for the gel digestion and liquid digestion samples, respectively. The 
contrary could be observed for the soluble samples (S3 and S3w), for both digestions, since 
the percentage of membrane proteins were lower comparing with soluble proteins, 
approximately 40% of membrane proteins in all soluble samples. This result was also expected, 
once during the subproteome fractionation procedure there was an enrichment of membrane 
proteins in the pellets (membrane samples).   
  In Supplementary figure 8.12 are represented the Venn Diagrams illustrating the number 
of shared or unique proteins from liquid and gel digestion that were identified by mass 
spectrometry. BioVenn software analysis was performed (http://www.cmbi.ru.nl/cdd/biovenn/) 
using diagrams with area-proportional to the number of identifications. The Venn Diagrams 
showed that approximately 630 proteins were commonly identified between gel and liquid 
digestion for samples E3, M3 and M3w, in the S3 samples 601 proteins were common and for 
S3w only 208 once the total number were lower (612 proteins) comparing with the other 
samples. The results obtained revealed that the number of identified proteins for all samples 
that were digested by in-gel digestion was higher comparing with the samples digested by the 
liquid approach. In gel digestion samples were also identified with a higher number of unique 
proteins comparing with liquid digestion.  Although gel digestion being a more time consuming 
procedure, this results showed that for a higher protein identification by mass spectrometry 
the in-gel digestion procedure is a better technique comparing with a liquid digestion 
procedure. A similar comparison between liquid and gel digestions was already done by a 
colleague in the group and the conclusion was the same, plus the reproducibility of the gel 
digestion technique was higher too, as well as, the results presented a lower coefficient of 
variation (Anjo et al, 2014, accepted).  
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Supplementary Figure 8.12: Venn Diagrams illustrating the number of shared or unique proteins 
from liquid and gel digestion that were identified by Mass spectrometry. A- Venn diagram showing 
the distribution of the shared and unique proteins between E3 sample digested in gel and E3 sample digested by 
the liquid approach. The combined protein number is 1080. B- Venn diagram showing the distribution of the 
shared and unique proteins between M3 sample digested in gel and M3 sample digested by the liquid approach. 
The combined protein number is 1190; C- Venn diagram showing the distribution of the shared and unique 
proteins between M3w sample digested in gel and M3w sample digested by the liquid approach. The combined 
protein number is 979; D- Venn diagram showing the distribution of the shared and unique proteins between S3 
sample digested in gel and S3 sample digested by the liquid approach. The combined protein number is 971; E- 
Venn diagram showing the distribution of the shared and unique proteins between S3w sample digested in gel 
and S3w sample digested by the liquid approach. The combined protein number is 612.                  
D 
C B 
Total numer:1080 Total numer:979 
Total numer:1190 
A 
Total numer:971 Total numer: 612 
